An aerosolisable formulation, a mesh, aerosol provision systems and methods for forming aerosol

The mesh design in aerosol generators addresses the sensory gap in non-combustible aerosol provision systems by optimizing temperature and particle size distribution, enhancing the cigarette-like experience through improved aerosol generation.

WO2026234388A2PCT designated stage Publication Date: 2026-11-12NICOVENTURES TRADING LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/GB2026/050790
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-11
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing aerosol provision systems fail to replicate the sensory experience of smoking traditional cigarettes, particularly in terms of aroma and sensation, due to inadequate temperature distribution and particle size control in aerosol generation.

Method used

A mesh for an aerosol generator with first and second filaments having different current densities, configured to create varying temperature zones and particle size distributions, optimized for aerosol generation between 50°C and 250°C, using a ferritic iron-chromium-aluminium alloy.

Benefits of technology

The mesh design enhances the user experience by providing a more cigarette-like aerosol with reduced harshness and irritation, achieving desirable particle sizes and temperature zones for improved sensory replication.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GB2026050790_12112026_PF_FP_ABST
    Figure GB2026050790_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed is a mesh for an aerosol generator in an aerosol provision system, the mesh comprising first and second filaments forming interstices, wherein: the first and second filaments have different current densities; and one or more of the interstices of the mesh are bounded by both the first and the second filaments. Also disclosed are aerosolisable formulations, aerosol provision systems and methods for forming aerosol.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0002] An aerosolisable formulation, a mesh, aerosol provision systems and methods for forming aerosol

[0003] Technical Field

[0004] The following disclosure seeks to provide a mesh for an aerosol generator in an aerosol provision system with an improved temperature distribution, which impacts aerosol properties, as well as aerosol provision systems and methods for forming aerosol.

[0005] Background

[0006] Smoking articles such as cigarettes, cigars, and the like, burn tobacco during use to create tobacco smoke. Alternatives to these types of articles release an inhalable aerosol or vapour by releasing compounds from a substrate material by heating without burning. These may be referred to as non-combustible smoking articles, aerosol-generating assemblies, noncombustible aerosol provision systems, or the like. One example of such a product is a heating device which releases compounds by heating, but not burning, a solid aerosolisable material. This solid aerosolisable material may, in some cases, contain a tobacco material. The heating volatilises at least one component of the material, typically forming an inhalable aerosol. These products may be referred to as heat-not-burn devices, tobacco heating devices or tobacco heating products. Various different arrangements for volatilising at least one component of the solid aerosolisable material are known.

[0007] As another example, there are e-cigarette / tobacco heating product hybrid devices, also known as electronic tobacco hybrid devices. These hybrid devices contain a liquid source, which may or may not contain nicotine, which is vaporised by heating to produce an inhalable vapour or aerosol. The device additionally contains a solid aerosolisable material, which may or may not contain a tobacco material, and components of this material are entrained in the inhalable vapour or aerosol to produce the inhaled medium. A further alternative is vapour products which are handheld, battery-powered devices that heat a liquid to produce an inhalable aerosol, commonly known as vapour.

[0008] Summary

[0009] One aspect of the invention described herein provides a mesh for an aerosol generator in an aerosol provision system, the mesh comprising first and second filaments forming interstices,DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0010] wherein: the first and second filaments have different current densities; and one or more of the interstices of the mesh are bounded by both the first and the second filaments.

[0011] Another aspect of the invention described herein provides a mesh for an aerosol generator in an aerosol provision system, the mesh comprising first and second filaments forming interstices, wherein:

[0012] a) the first and second filaments have different current densities;

[0013] b) one or more of the interstices of the mesh are bounded by both the first and the second filaments; and

[0014] c) the first and second filaments are configured to be respectively heated by a power source to a first temperature T 1 and a second temperature T2, wherein the ratio of T1 to T2 is in the range of 1: 1.25 to 1:2.5.

[0015] Another aspect of the invention described herein provides a mesh for an aerosol generator in an aerosol provision system, the mesh comprising first and second filaments forming interstices, wherein:

[0016] a. the first and second filaments have different current densities;

[0017] b. one or more of the interstices of the mesh are bounded by both the first and the second filaments; and

[0018] c. the first and second filaments are arranged in the mesh to form:

[0019] i. two or more low current density zones and at least one high current density zone; or

[0020] ii. two or more high current density zones and at least one low current density zone.

[0021] Another aspect of the invention described herein provides an aerosol generator in an aerosol provision system, the aerosol generator comprising a heater for heating a liquid to generate an aerosol and an air path for delivering the aerosol to a user, the heater comprising first and second zones, wherein: the first and second zones have different current densities or temperatures; and the heater is arranged parallel to the flow of air in the air path.

[0022] Another aspect of the invention described herein provides an aerosol generator for an aerosol provision system, the aerosol generator configured to generate aerosol from an aerosolisable formation by resistive heating, the aerosol generator having a mesh comprising filaments forming interstices, wherein:

[0023] • 30-40% of the aerosol generation surface area is configured to operate at 100> T>50;DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0024] • 15-25% of the aerosol generation surface area is configured to operate at 150> T>100;

[0025] • 10-20% of the aerosol generation surface area is configured to operate at 200> T>150; and

[0026] • 20-35% of the aerosol generation surface area is configured to operate at 250> T>200, where T is temperature in °C.

[0027] Another aspect of the invention described herein provides a cartridge comprising an aerosolisable formation, the formulation comprising a composition to provide a tobacco aroma, the composition comprising one or more compounds selected from: C6 to C18 substituted pyrazines, sesquiterpenes or terpene alcohols, C5 to C24 fatty acids, C7 to C18 aromatic alcohols, C3 to C24 aliphatic esters, C8 to C18 aromatic esters, and C4 to C18 lactones.

[0028] Another aspect of the invention described herein provides an aerosolised formulation obtainable by aerosolising a formulation comprising a composition to provide a tobacco aroma, the composition comprising one or more compounds selected from: C6 to C18 substituted pyrazines, sesquiterpenes or terpene alcohols, C5 to C24 fatty acids, C7 to C18 aromatic alcohols, C3 to C24 aliphatic esters, C8 to C18 aromatic esters, and C4 to C18 lactones, wherein the aerosolised formulation has:

[0029] i. a Dv50 particle size of 0.40 – 0.50 µm; and / or

[0030] ii. a Dv90 particle size of 0.70 – 1.00 µm.

[0031] Another aspect of the invention described herein provides a method of generating an aerosol, the method comprising aerosolising an aerosolisable formulation comprising a composition to provide a tobacco aroma, the composition comprising one or more compounds selected from: C6 to C18 substituted pyrazines, sesquiterpenes or terpene alcohols, C5 to C24 fatty acids, C7 to C18 aromatic alcohols, C3 to C24 aliphatic esters, C8 to C18 aromatic esters, and C4 to C18 lactones, to provide an aerosol having:

[0032] i. a Dv50 particle size of 0.40 – 0.50 µm; and / or

[0033] ii. a Dv90 particle size of 0.70 – 1.00 µm.

[0034] The claimed invention further provides corresponding functional means and further provides additional embodiments as claimed in the dependent claims.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0035] In some examples, the mesh comprises multiple first filaments having a first current density and multiple second filaments having a second current density.

[0036] In some examples, the mesh comprises multiple parallel first filaments and multiple parallel second filaments, wherein the first and second filaments are perpendicular.

[0037] In some examples, at least two opposing sides of one or more interstices are bounded by filaments having a higher current density than filaments bounding other sides of the one or more interstices.

[0038] In some examples, all interstices in the mesh are bounded by both the first and second filaments having different current densities.

[0039] In some examples, the second filament(s) have a second current density substantially a factor of 2x to 15x higher than the first current density of the first filament(s).

[0040] In some examples, the second filament(s) have a second current density substantially a factor of 3x to 7x, 4x to 6x or 5x higher than the first current density of the first filament(s). In some examples, the mesh comprises different temperature zones having operating temperatures between 50 and 250°C.

[0041] In some examples, the first and second filaments are configured to be respectively heated by a power source to a first temperature T 1 and a second temperature T2, wherein the ratio of T1 to T2 is in the range of 1: 1.25 to 1:2.5.

[0042] In some examples, the first and second filaments are arranged in the mesh to form:

[0043] a) two or more low current density zones and at least one high current density zone; or b) two or more high current density zones and at least one low current density zone. In some examples:

[0044] a. 30-40% of an aerosol generation surface area is configured to operate at 100> T>50; and / or

[0045] b. 15-25% of an aerosol generation surface area is configured to operate at 150> T>100; and / or

[0046] c. 10-20% of an aerosol generation surface area is configured to operate at 200> T>150; and / or

[0047] d. 20-35% of an aerosol generation surface area is configured to operate at 250> T>200, where T is temperature in °C.

[0048] In some examples:

[0049] a. first filament(s) and / or the second filaments comprise a ferritic iron-chromium- aluminium alloy (FeCrAI alloy); and / or

[0050] b. the first current density of the first filament(s) is within the range of 0.1 -1.0 x108A / M2; and / or

[0051] c. the second current density of the second filament(s) is within the range of 2.0- 3.0 x108A / M2.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0052] In some examples:

[0053] a. the first filament(s) have a diameter or cross-sectional dimension of substantially 0.12-0.18 mm; and / or

[0054] b. the second filament(s) have a diameter or cross-sectional dimension of substantially 0.05-0.09 mm.

[0055] In some examples:

[0056] a. the first filament(s) have a diameter or cross-sectional dimension of substantially 0.15 mm; and / or

[0057] b. the second filament(s) have a diameter or cross-sectional dimension of substantially 0.07 mm.

[0058] In some examples, the mesh comprises a connecting portion for connecting the filaments to a power supply.

[0059] In some examples, the aerosol generation surface area comprises the area of the aerosol generation surface configured to operate between 50 and 250°C in use.

[0060] In some examples, the aerosol generation surface area comprises the planar, rectangular area surrounding the mesh.

[0061] In some examples, one or more interstices in the mesh are substantially hexagonal.

[0062] In some examples, all interstices in the mesh are substantially hexagonal.

[0063] In some examples, the mesh comprises a column or row of substantially hexagonal interstices along a centreline of the mesh.

[0064] In some examples, the filaments provide a lower current density region along a centreline of the mesh, bounded by a higher current density region either side of the centreline.

[0065] In some examples, the substantially hexagonal interstices have:

[0066] a. a major width (lwi) of substantially 1.8-2.2 mm or substantially 2.0 mm; and / or b. a minor width (lW2) of substantially 0.6-1.0 mm or substantially 0.8 mm; and / or c. a length (II) of substantially 0.45-0.50 mm or substantially 0.47 mm; and / or d. an angle 0 between second filaments of substantially 20-40°, 25-35° or substantially 30°; and / or

[0067] e. an angle 0 between filaments extending from the major width (lwi) to the minor width (lW2) of substantially 20-40°, 25-35° or substantially 30°.

[0068] In some examples, the interstices are substantially rectangular, having:

[0069] a. a width (lw) of substantially 1.2-1.6 mm or substantially 1.4 mm; and / or b. a length (II) of substantially 0.45-0.50 mm or substantially 0.47 mm. In some examples, the interstices are square, having substantially equal length and width dimensions of substantially 0.70-0.90 mm or substantially 0.75-0.85 mm.

[0070] In some examples, an aerosol provision system comprises:

[0071] a. an aerosol generator having the mesh of any preceding mesh clause; orDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0072] b. the aerosol generator of any preceding aerosol generator clause.

[0073] In some examples, the aerosol provision system further comprising a wicking material in contact with the mesh, for supplying aerosolisable material to the mesh, for aerosolisation. In some examples, the aerosol provision system further comprising an air flow path extending parallel to a length or width of the mesh.

[0074] In some examples, the aerosol provision system further comprising an aerosolisable formation, the formulation comprising a composition to provide a tobacco aroma, the composition comprising one or more compounds selected from: C6 to C18 substituted pyrazines, sesquiterpenes or terpene alcohols, C5 to C24 fatty acids, C7 to C18 aromatic alcohols, C3 to C24 aliphatic esters, C8 to C18 aromatic esters, and C4 to C18 lactones. In some examples, the cartridge comprising an aerosol generator and an air flow path extending parallel to a length or width of the aerosolisation surface of the aerosol generator. In some examples, the aerosolised formulation having:

[0075] i. a Dv50 particle size of 0.42 – 0.47 µm; and / or

[0076] ii. a Dv90 particle size of 0.74 – 0.94 µm.

[0077] In some examples, the aerosolised formulation having:

[0078] i. a Dv50 particle size of 0.40 – 0.44 µm; and / or

[0079] ii. a Dv90 particle size of 0.70 – 0.82 µm.

[0080] In some examples, the aerosolised formulation having:

[0081] i. a Dv50 particle size of 0.42 – 0.44 µm; and / or

[0082] ii. a Dv90 particle size of 0.74 – 0.79 µm.

[0083] In some examples, the aerosolised formulation having a Dv10 particle size of 0.20-0.30 µm or 0.24-0.26 µm.

[0084] In some examples, the method comprising aerosolising the formulation using the mesh, the aerosol generator, the aerosol provision system or the cartridge.

[0085] These and other features, aspects and advantages of the disclosure will be apparent from the following detailed description and drawings. The invention includes any combination of two, three, four, or more of the above-noted examples as well as combinations of any two, three, four, or more features or elements set forth in this disclosure, regardless of whether such features or elements are expressly combined in a specific example description herein. This disclosure is intended to be read holistically such that any separable features or elements of the disclosed invention, in any of its various aspects and examples, should be viewed as intended to be combinable unless the context clearly dictates otherwise.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0086] Brief description of the figures

[0087] Embodiments of the disclosure will now be described, by way of example only, with reference to the accompanying drawings, in which:

[0088] Figure 1 is a schematic illustration of a first mesh for an aerosol generator in an aerosol provision system;

[0089] Figure 2 is a schematic illustration of a second mesh for an aerosol generator in an aerosol provision system;

[0090] Figure 3 illustrates an operating temperature profile of the mesh of figure 2;

[0091] Figure 4 is a schematic illustration of an aerosol provision system comprising the mesh of figure 2;

[0092] Figures 5-7 are particle size distribution plots for aerosol generated from 3 sample liquids; and Figures 8-9 identify the location of irritation in accordance with some examples.

[0093] Detailed Description

[0094] Aspects and features of certain examples are described herein. Some aspects and features may be implemented conventionally and these are not described in detail, for brevity.

[0095] It is to be understood that this disclosure is not limited to the particular configurations, process steps, and materials disclosed herein as such configurations, process steps, and materials may vary somewhat. It is also to be understood that the terminology employed herein is used for the purpose of describing particular embodiments only and is not intended to be limiting since the scope will be limited only by the appended claims and equivalents thereof.

[0096] As used in this specification and the claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Reference to "dry % by weight" or "dry weight basis" refers to weight on the basis of dry ingredients (i.e., all ingredients except water or carrier). Reference to "wet weight" refers to the weight of the formulation or composition including water or carrier. Unless otherwise indicated, reference to "% by weight" (or “% by weight”) of formulation or composition reflects the total wet weight of the formulation or composition (i.e., including water / carrier). Unless otherwise indicated, all % values are calculated on a weight basis, and are provided with reference to the total weight of the product in which the substance is present.

[0097] In this specification, unless otherwise stated, the term "about" modifying the quantity of an ingredient in the formulation or employed in the methods refers to variation in the numerical quantity that can occur, for example, through typical measuring and liquid handling proceduresDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0098] used for making concentrates or use solutions in the real world; through inadvertent error in these procedures; through differences in the manufacture, source, or purity of the ingredients employed to make the formulation, or to carry out the methods; and the like. The term “about” also encompasses amounts that differ due to different equilibrium conditions for a formulation or composition resulting from a particular initial mixture. Whether or not modified by the term "about", the claims include equivalents to the quantities.

[0099] The ranges provided herein relate to preferred amounts of each of the compound groups. Each of these ranges may be taken alone or combined with one or more other compound group range(s) to provide a preferred example of the invention.

[0100] As used herein, “substantially free” means no more than trace amounts, i.e. the amount of the substance(s) concerned is negligible. In various examples, “substantially free” means no more than 1000 ppm, preferably no more than 100 ppm, more preferably no more than 10 ppm, even more preferably no more than 1 ppm of the substance(s) concerned.

[0101] In all aspects of the present disclosure, the disclosure includes, where appropriate, all enantiomers and tautomers of the compounds disclosed herein. A person skilled in the art will recognise compounds that possess optical properties (one or more chiral carbon atoms) or tautomeric characteristics. The corresponding enantiomers and / or tautomers may be isolated / prepared by methods known in the art. Some of the compounds disclosed herein may exist as stereoisomers and / or geometric isomers - e.g. they may possess one or more asymmetric and / or geometric centres and so may exist in two or more stereoisomeric and / or geometric forms. The present disclosure contemplates the use of all the individual stereoisomers and geometric isomers of those compounds, and mixtures thereof. The terms used in the claims encompass these forms.

[0102] As used herein, an alkyl group can be a substituted or unsubstituted, linear or branched chain saturated radical. Examples of alkyl groups include methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl, hexadecyl, heptadecyl, octadecyl, nondecyl, eicosyl, and isomeric forms thereof. Cycloalkyl groups are derived from cycloalkanes by removal of a hydrogen atom from a ring carbon atom; they include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 2-methylcyclopentyl, 2,3-dimethyl-cyclobutyl, 4-methylcyclobutyl, 3-cyclopentylpropyl, and the like.

[0103] As used herein, an alkenyl group can be a substituted or unsubstituted, linear, branched or cyclic unsaturated radical. An alkenyl group thus contains one or more carbon-carbon double bonds. Examples of alkenyl groups include ethenyl, propenyl, butenyl, pentenyl, hexenyl,DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0104] heptenyl, octenyl, nonenyl, decenyl, dodecenyl, hexadecenyl, heptadecenyl, octadecenyl, nondecenyl, eicosenyl, and isomeric forms thereof. Cycloalkenyl groups include cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, and the like, and isomeric forms thereof.

[0105] As used herein, an aromatic group is a substituted or unsubstituted group derived from arenes by removal of a hydrogen atom from a ring carbon atom. Aryl groups include phenyl, tolyl, xylyl, naphthyl, biphenylyl, and the like.

[0106] A cigarette, also known as a factory-made cigarette or ‘FMC’, gives rise to a cigarette-like or FMC-like experience when smoked by a consumer. Such an experience can have various dimensions, including sense, taste and flavour dimensions. By the ‘sense’ of a cigarette, is meant the overall feel of smoking a cigarette which includes attributes such as impact, irritation, harshness, mouth drying, and mouth coating or mouthfeel. By the “taste” of a cigarette is meant the overall taste of smoking a cigarette including tastes such as hay-like, bread-like, smoky, tannin, resinous, musk, etc., and by the “flavour” of a cigarette is meant the overall flavour of smoking cigarette including flavours such as creamy, fruity, floral, green, spicy, savoury, roasted, woody, etc.

[0107] As noted above, there are several alternative means by which a consumer can replicate the smoking experience. These include e-cigarettes and tobacco heating devices which provide the consumer with an inhalable aerosol. One potential drawback with such devices is, however, that they may fail to completely replicate one or more of the dimensions associated with the FMC-like experience. One dimension that is particularly critical for consumers is “sensation”. With an inhalable aerosol, sensation is delivered by said aerosol meaning that when a consumer is seeking an “FMC-like experience” with a heating device (whether with a solid, liquid, gel or hybrid aerosolisable formulation(s)), it is desirable for the aerosol to replicate that of smoking a cigarette, i.e. for the aroma to be tobacco-like and deliver a richness and complexity comparable to smoking a cigarette.

[0108] The present disclosure relates to a mesh design which can be used in an aerosol generator, consumable or cartridge for a substance delivery system to improve the sensory experience. In particular, the inventors have identified that the aerosolisable formulations disclosed herein have desirable particle sizes, reducing harshness and irritation, particularly when used with the mesh arrangement disclosed herein.

[0109] The present disclosure may therefore allow for a more user-friendly and improved cigarettelike experience to be created. This has many benefits; many consumers who smoke traditionalDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0110] cigarettes may previously have been reluctant or unwilling to use non-combustible aerosol provision devices, e.g. heat-not-burn, hybrid or vapour devices, or oral compositions, because the experience of using these devices or compositions may differ from the experience of burning and smoking a cigarette. The present disclosure may, however, allow for consumers to get the same or similar experience to smoking a cigarette when using oral compositions and / or non-combustible aerosol provision systems. For example, when using the composition of the present disclosure in a non-combustible aerosol provision system, a more ‘cigarettelike’ experience and / or aerosol can be created compared to using a previously-known or commercially available composition for use in such devices.

[0111] For ease of reference, these and further aspects of the present invention are now discussed under appropriate section headings. However, the teachings under each section are not necessarily limited to each particular section. In other words, particular sections of the description are not to be read in isolation from other sections.

[0112] Mesh design

[0113] Various examples of the disclosure are directed to a mesh 100 for an aerosol generator in an aerosol provision system. The mesh 100 may be utilised in an aerosol generator in an aerosol provision system, particularly with the aerosol generator arranged parallel to a flow of air along an air flow path from an air inlet to an aerosol outlet. Ideally, the air flow path from the air inlet to the aerosol outlet is straight.

[0114] The characteristics of the mesh used in a mesh aerosol generator may impact the aerosol characteristics, including the aerosol temperature and particle size. In some examples of the disclosure, the mesh 100 comprises filaments having different current density (A / M2), which quantifies the amount of current flowing through a unit area, thus lower resistivity provides higher current density. Varying the current density (or resistivity) thereby varies the heat generated in the mesh. Providing different temperature zones, e.g. by using first and second filaments Fi, F2 having different current densities, provides an aerosolisation surface with different heating zones that can be particularly well-suited to the formulations described herein, e.g. providing a desirable particle size distribution with reduced deposition on the aerosol generator, where such deposition can lead to reduced functionality I performance.

[0115] The mesh 100 may comprise filaments configured to provide different temperature zones having operating temperatures suitable for aerosolisation, such as between 50 and 250°C. The mesh 100 may provide longitudinally arranged hotter and cooler zones - where air spendsDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0116] longer in contact with the heater, cooler areas may prevent overheating of the air whilst hotter areas may give more instant aerosol. In particular, the mesh 100 (or an aerosol generator comprising the mesh 100) may provide zones operating at different temperatures, particularly comprising zones operating at a temperature T in °C of 100> T>50, 150> T>100, 200> T>150; and 250> T>200. In some examples, the filaments are configured to be respectively heated by a power source to a first temperature T 1 and a second temperature T2, wherein the ratio of T1 to T2 is in the range of 1:1.25 to 1:2.5. In some examples, the mesh filaments are arranged to form two or more low current density zones and at least one high current density zone; or two or more high current density zones and at least one low current density zone. Further, providing the aerosol generator aligned with (parallel to) an air flow path from an air inlet to an aerosol outlet reduces disruption of the air flow, which may otherwise negatively impact particle size distribution and deposition.

[0117] Figure 1 illustrates a mesh 100 for an aerosol generator in an aerosol provision system. The mesh 100 comprises first and second filaments Fi, F2 forming interstices I. In this example, the first and second filaments F1, F2 have different current densities and one or more interstices of the mesh 100 are bounded by both the first and the second filaments F1, F2. In other words, one or more of the interstices are formed by the first and the second filaments F1, F2.

[0118] In figure 1, the mesh 100 is rectangular and comprises multiple parallel (horizontal) first filaments having a first current density and multiple parallel (vertical) second filaments having a second current density. The first and second filaments F1, F2 are perpendicular and all interstices of the mesh 100 are bounded by the first and the second filaments F1, F2. In particular, each of the interstices has opposing horizontal sides formed / bounded by the horizontal first filaments, and opposing vertical sides formed / bounded by the vertical second filaments. The vertical spacing between each of the first filaments and the horizontal spacing between each of the second filaments is constant, thus all interstices have the same dimensions, length (II) and width (lw).

[0119] The interstices may be substantially rectangular as shown in figure 1, e.g. having a width (lw) of substantially 1.2-1.6 mm or substantially 1.4 mm; and / or a length (II) of substantially 0.45-0.50 mm or substantially 0.47 mm. In other examples, the interstices are square, thus have substantially equal length and width dimensions e.g. of substantially 0.70-0.90 mm or substantially 0.75-0.85 mm. The primary aerosolisation portion 110 of the mesh 100, comprising the interstices, has an overall mesh length ML and mesh width Mw, although the total area that may function to generate aerosol may be larger, as discussed further below.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0120] The filaments have an electrical connecting portion 170 which supplies power to the filaments for generating heat by resistance and thereby produce aerosol from aerosol-generating material (not shown).

[0121] The first filaments Fi have a first current density Ji and the second filaments F2 have a second current density J2. A suitable ratio of the current densities may lie within the range of 2 to 15. For example, the second current density may be substantially a factor of 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x, 11x, 12x, 13x, 14x or 15x higher than the first current density.

[0122] The first and second filaments F1, F2 may have any cross-sectional shape, such as circular, square or rectangular and may have different dimensions and / or comprise different materials, to vary the current density. In particular, the first filament(s) may have a diameter or cross-sectional dimension (e.g. thickness, depth) of substantially 0.12-0.18 mm, optionally substantially 0.15 mm; and / or the second filament(s) may have a diameter or cross-sectional dimension of substantially 0.05-0.09 mm, optionally substantially 0.07 mm.

[0123] In some examples, the first current density of the first filament(s) is within the range of 0.1-1.0 x108A / M2. In some examples, the second current density of the second filament(s) is within the range of 2.0-3.0 x108A / M2. One suitable material for the filaments is ferritic iron-chromium-aluminium alloy (FeCrAI alloy).

[0124] Figure 2 illustrates a second mesh 100 for an aerosol generator in an aerosol provision system. The mesh 100 of figure 2 shares the same key features as the mesh 100 of figure 1, but here the overall shape of the mesh 100 and the shape / dimensions of the interstices differ. In figure 2, the primary aerosolisation portion 110 of the mesh 100 comprises interstices I1... I5 centrally aligned along a centreline CL. Again, the mesh 100 comprises first and second filaments F1, F2 forming interstices I and the first and second filaments F1, F2 have different current densities. In figure 2, all interstices of the mesh 100 are bounded by both the first and the second filaments F1, F2, where the horizontal sides are formed by first filaments F1 and the inclining / declining sides (<, >) are formed by second filaments F2. In this example, all of the first filaments F1 have a first current density Ji that is lower than a second current density J2 of the second filaments F2. The lower current density of the first filaments along (but perpendicular to) the centreline shown in figure 2 provides a lower temperature zone along the centreline, as shown in figure 3.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0125] In figure 2, the interstices are substantially hexagonal in shape and the centreline CL bisects the midpoint of two opposing sides of each interstice. The substantially hexagonal interstices of the mesh 100 may have:

[0126] • a major width (lwi) of substantially 1.8-2.2 mm or substantially 2.0 mm; and / or

[0127] • a minor width (lW2) of substantially 0.6-1.0 mm or substantially 0.8 mm; and / or

[0128] • a length (II) of substantially 0.45-0.50 mm or substantially 0.47 mm; and / or

[0129] • an angle 0 between second filaments of substantially 20-40°, 25-35° or substantially 30°; and / or

[0130] • an angle 0 between filaments extending from the major width (Iwi) to the minor width (lW2) of substantially 20-40°, 25-35° or substantially 30°.

[0131] Figure 2 also illustrates a length-ways spacing S between the first filaments that extend horizontally away from the primary aerosolisation portion 110 of the mesh 100. Spacing S may be substantially equal to lL.

[0132] Figure 3 illustrates the operating temperature profile of the mesh 100 of figure 2. The mesh 100 can provide multiple different temperature zones across the aerosol generation surface area, as outlined above. Generally speaking, the aerosol generation surface area is the planar surface area of the aerosol generator that functionally generates aerosol. In order to generate aerosol, the aerosol generator needs to be proximal to a suitable aerosol-generating material (aerosolisable formulation), operating at a suitable temperature (which may vary slightly depending on the formulation in use) and proximal to an air flow for the vapour to be entrained to form aerosol. In particular, the aerosol generation surface area may appropriately be defined as the area of the aerosol generation surface configured to operate between 50 and 250°C in use. In some examples, the aerosol generation surface may be the planar rectangular area surrounding the mesh, configured to operate between 50 and 250°C. As can be seen from figure 3, the entire mesh 100 operates at a temperature exceeding 100°C (figure 3 shows surface temperatures of the mesh filaments between 100-250°C). The planar rectangular area immediately surrounding the mesh 100 (shown in dashed lines in figure 3) has a temperature of 50-250°C, thus this area may be considered as the aerosol generation surface area.

[0133] The table below summarises proportions of the aerosol generation surface area operating in various temperature ranges in accordance with some examples. As one concrete but nonlimiting example, the ‘Fig.3 area ratio’ column indicates the specific area ratio of the planar,DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0134] rectangular area around the mesh 100 as modelled (shown in dashed lines in fig. 3) for the system of figure 4 having an aerosol generator comprising the mesh 100 of figures 2-3.

[0135]

[0136] In the example of figure 3:

[0137] • the second filaments forming the inclining / declining sides (<, >) of the mesh have a surface temperature of approximately 200-250°C

[0138] • the first filaments disposed between interstices, aligned along the centreline of the mesh 100, have a surface temperature of approximately 175-225°C (at the lower end along the centreline of the mesh and at the higher end proximal to the second filaments)

[0139] • the top and bottom first filaments that adjoin the connecting portion 170 have a surface temperature of approximately 150-200°C (at the lower end along the centreline of the mesh and at the higher end proximal to the second filaments)

[0140] • the first filaments that extend horizontally away from the primary aerosolisation portion 110 of the mesh 100 (i.e. that extend away from the interstices) and the connecting portion 170 itself have a surface temperature of approximately 100-150°C (at the higher end proximal to the second filaments)

[0141] • the centres of the interstices have a temperature of approximately 50-100°C

[0142] • the rest of the chamber is below 50°C

[0143] Figure 4 illustrates an aerosol provision system 1 comprising an aerosol generator having the mesh 100 of figure 2. The mesh 100 is mounted on a wicking material 150, such as a cotton or ceramic material, which supplies the mesh 100 with an aerosol-generating material (aka an aerosolisable formation), for aerosolisation. The wicking material 150 may receive aerosolgenerating material from a liquid supply / reservoir, or the wicking material 150 may comprise the liquid supply. The mesh 100 is electrically connected to a power supply (not shown) via connecting portion 170 and plate-shaped contact portion 180.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0144] The system 1 comprises an air flow path, indicated by arrows in figure 4, from an inlet to an outlet, where the flow path extends parallel to a length of the mesh 100. In use, the air flows across the mesh 100 and entrains vapour generated by the mesh 100. In some examples, the air flow path is substantially straight between the inlet and the outlet. As shown in figure 4, the primary aerosolisation region 110 may be parallel to the flow of air along the air path from the inlet to the outlet. Further, the air flow path may be centrally aligned with the centreline CL of the mesh and centrally aligned with the primary aerosolisation region 110 comprising interstices. In some examples, the inlet and / or outlet have a similar width to that of the primary aerosolisation portion 110 of the mesh 100. In figure 4, the outlet has a width substantially the same as the major width (lwi) of the hexagonal interstices in the mesh 100.

[0145] The system 1 may comprise the aerosol generating material, particularly an aerosolisable formulation as outlined herein. The system 1 may be one part of a two-part system, e.g. the system 1 may be a cartridge for use with a reusable device part having a power supply, or the system 1 may be a reusable device part having a power supply for use with a removable supply of aerosol-generating material. Alternatively, the system 1 may be a single-part disposable system comprising both a power supply and aerosol-generating material.

[0146] Aerosolisable Formulation

[0147] In some examples, the aerosol provision system of the present disclosure may comprise an aerosolisable formulation or aerosol generator material. The formulation or material may otherwise be referred to herein as a consumable. The consumable may comprise a composition to provide a tobacco aroma. By the term “tobacco aroma” is meant an aroma that simulates the aroma from burning or smoking a cigarette containing tobacco. This aroma results from various volatile compounds naturally-present in the tobacco and / or produced during curing, aging and / or processing of the tobacco leaves. Many of the compounds present in the composition of the present disclosure thus have a boiling point of less than 250°C and / or a molecular weight of about 50 to about 500 g / mol. The molecular weight is the ratio of the mass of a molecule to the unified atomic mass unit (as defined in the IIIPAC Gold Book); it is also referred to in the art as the relative molar mass. Hence, the compounds present in the composition of the present disclosure have the potential to be aerosolised when the composition is used in a substance delivery system which is a non-combustible aerosol provision system or device, such as a heat-not-burn or vaping device or system. It will be understood by the person skilled in the art that the composition of the present disclosure is not raw tobacco. As used herein, the term “raw tobacco” refers to any part of a plant of theDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0148] Nicotiana species (e.g. leaf or stem) that has been harvested from the ground but not otherwise subjected to any processing steps.

[0149] The composition may comprise one or more compounds selected from: C6 to C18 substituted pyrazines, sesquiterpenes or terpene alcohols, C5 to C24 fatty acids, C7 to C18 aromatic alcohols, C3 to C24 aliphatic esters, C8 to C18 aromatic esters, and C4 to C18 lactones. _This composition may be used with or without a plant (e.g. tobacco) material. When used in combination with a tobacco material such as a tobacco extract, the extract may first be analysed for the presence of one or more of the compounds, and then supplemented with additional compounds as disclosed herein in order to improve the FMC-like flavour experience obtained when used in the present disclosure. Exemplary compounds are described below.

[0150] Substituted Pyrazines and Pyridines

[0151] The composition of the present disclosure may include at least one compound selected from C6 to C18 substituted pyrazines. The carbon atom range “C6 to C18” refers to the compound as a whole, i.e. the substituted pyrazine. In some examples, the C6 to C18 substituted pyrazines are defined by their molecular weight; the molecular weight of each C6 to C18 substituted pyrazine may be from about 90 g / mol to about 150 g / mol.

[0152] In some examples the C6 to C18 substituted pyrazine comprises substituents selected from alkyl groups, alkenyl groups, aryl groups, hydroxyl groups, carboxyl groups, alkoxy groups, sulfhydryl groups, thionyl groups, sulfide groups, and combinations thereof. In some examples the C6 to C18 substituted pyrazine comprises substituents selected from alkyl groups, alkenyl groups, carboxyl groups (e.g. ketones), hydroxyl groups, alkoxy groups, sulfhydryl groups, and combinations thereof. In some examples the C6 to C18 substituted pyrazine comprises substituents selected from alkyl groups, alkenyl groups, carboxyl groups (e.g. ketones), alkoxy groups, sulfhydryl groups, and combinations thereof. The alkyl groups are preferably C1 to C6 alkyl groups; the alkenyl groups are preferably C2 to C6 alkenyl groups; and the carboxyl groups are preferably ketones or aldehydes such as C2 to C6 ketones.

[0153] In some examples, the composition includes at least one C6 to C18 substituted pyrazine selected from pyrazine, trimethyl- (e.g. 2,3,5-trimethylpyrazine); pyrazine, 2,6-diethyl; pyrazine, tetramethyl- (e.g. 2,3,5,6-tetramethylpyrazine); 2-methylpyrazine; 2,3-dimethylpyrazine; 2,5-dimethyl pyrazine; 2,6-dimethyl pyrazine; 2-ethenyl-pyrazine; 2-methyl-3-butyl-pyrazine; 2-ethylpyrazine; isopropenylpyrazine; acetyl pyrazine; 2-ethyl-6-methylpyrazine; 2-methoxy-3-methylpyrazine; 2,3-diethylpyrazine, 2-methyl-3-DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0154] methylsulfanylpyrazine; 1-pyrazin-2-ylethanone; cyclohexylmethylpyrazine; deoxyfructosazine; and combinations thereof.

[0155] In some examples, the composition includes at least two C6 to C18 substituted pyrazines selected from 2,3,5-trimethylpyrazine; pyrazine, 2,6-diethyl-;2,3,5,6-tetramethylpyrazine; 2-methylpyrazine; 2,3-dimethylpyrazine; 2,5-dimethyl pyrazine; 2-ethylpyrazine; acetyl pyrazine; 2-ethyl-6-methylpyrazine; 2-methoxy-3-methylpyrazine; 2-methyl-3-methylsulfanylpyrazine; 1-pyrazin-2-ylethanone; 2,6-dimethylpyrazine; 2-ethenyl-pyrazine; 2-methyl-3-butyl-pyrazine; cyclohexylmethylpyrazine; deoxyfructosazine; and combinations thereof.

[0156] In some examples, the composition comprises a methyl-pyrazine (e.g. 2-methylpyrazine), and at least one additional C6 to C18 substituted pyrazine selected from 2,3-dimethylpyrazine; 2,5-dimethyl pyrazine; 2-ethylpyrazine; 2-ethyl-6-methylpyrazine; 2,6-dimethylpyrazine; 2-ethenyl-pyrazine; 2-methyl-3-butyl-pyrazine; and combinations thereof.

[0157] In some examples the composition comprises a dimethyl-pyrazine, and at least one additional C6 to C18 substituted pyrazine selected from 2-ethylpyrazine; 2-ethyl-6-methylpyrazine; 2-ethenyl-pyrazine; 2-methyl-3-butyl-pyrazine; and combinations thereof.

[0158] In some examples, the composition comprises an ethenyl-pyrazine, and at least one additional C6 to C18 substituted pyrazine selected from 2-ethylpyrazine; 2-ethyl-6-methylpyrazine; 2-ethenyl-pyrazine; 2-methyl-3-butyl-pyrazine; and combinations thereof.

[0159] In some examples, each C6 to C18 substituted pyrazine is present in the composition an amount from about 0.1 pg / g to about250 pg / g. In some examples, each C6 to C18 substituted pyrazine is present in the composition in an amount from about 0.1 pg / g to about 50 pg / g. In some examples, each C6 to C18 substituted pyrazine is present in the composition in an amount from about 0.1 pg / g to about 25 pg / g. When incorporated into a consumable, the composition may be present at about 5% w / w to about 30% w / w meaning that these amounts will be adjusted accordingly relative to the total weight of the consumable. In some examples, the composition may be present at about 5% w / w to about 20% w / w. In some examples, the composition may be present at about 5% w / w to about 15% w / w. For example, at an inclusion level of 10% w / w for the composition, the amount of each C6 to C18 substituted pyrazine may be about 0.00001 wt% to about 0.025 wt%, about 0.00001 wt% to about 0.05 wt%, or about 0.00001 wt% to about 0.025 wt%, based on the total weight of the consumable.

[0160] In some examples, the total amount of C6 to C18 substituted pyrazine in the composition is from about 1 pg / g to about 350 pg / g. In some examples, the total amount of C6 to C18 substituted pyrazine in the composition is from about 1 pg / g to about 100 pg / g. In someDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0161] examples, the total amount of C6 to C18 substituted pyrazine in the composition is from about 5 pg / g to about 50 pg / g. When incorporated into a consumable, the composition may be present at about 5% w / w to about 30% w / w meaning that these amounts will be adjusted accordingly relative to the total weight of the consumable. In some examples, the composition may be present at about 5% w / w to about 20% w / w. In some examples, the composition may be present at about 5% w / w to about 15% w / w. For example, at an inclusion level of 10% w / w for the composition, the total amount of C6 to C18 substituted pyrazine may be about 0.0001 wt% to about 0.035 wt%, about 0.0001 wt% to about 0.01 wt%, or about 0.0005 wt% to about 0.005 wt%, based on the total weight of the consumable.

[0162] In some examples, the at least one C6 to C18 substituted pyridine comprises substituents selected from alkyl groups, alkenyl groups, aryl groups, hydroxyl groups, carboxyl groups, alkoxy groups, and combinations thereof. In some examples the C6 to C18 substituted pyridine comprises substituents selected from alkyl groups, alkenyl groups, carboxyl groups (e.g. ketones and / or aldehydes), hydroxyl groups, alkoxy groups, and combinations thereof. In some examples the C6 to C18 substituted pyridine comprises substituents selected from alkyl groups, alkenyl groups, carboxyl groups (e.g. ketones or aldehydes), and combinations thereof. The alkyl groups are preferably C1 to C6 alkyl groups; the alkenyl groups are preferably C2 to C6 alkenyl groups; and the carboxyl groups are preferably ketones or aldehydes such as C2 to C6 ketones

[0163] In some examples, the composition comprises at least one C6 to C18 substituted pyridine which is not an alkaloid. In some examples, this at least one C6 to C18 substituted pyridine is selected from: n-phenylpyridine-3-carboxamide; 1-(5-methylpyridin-3-yl)ethanone; thionicotinic acid; 3-(2,3-dihydro-1h-pyrrol-5-yl)pyridine; 3-[1,2,3,6-tetrahydropyridin-2-yl]pyridine; 3-phenylpyridine; 2-(pyridin-2-ylmethyl)pyridine; 3-methyl-2-phenylpyridine; 1-pyridin-3-ylethanone; 2-(3-pyridinyl)-2-pyrroline; ethyl-pyridine; methyl-pyridine; methyl-ethyl-pyridine; ethenyl-pyridine; acetyl pyridine; 2,6-bis(hydroxymethyl)-3-pyridinol; 1-propanone, 1-(4-methyl-2-pyridinyl)-; pyridinecarboxaldehyde; and combinations thereof.

[0164] When present, each C6 to C18 substituted pyridine which is not an alkaloid may be present in the composition in an amount of from about 0.1 pg / g to about 300 pg / g. In some examples, the total amount of C6 to C18 substituted pyridines which are not alkaloids may be about 1 pg / g to about 500 pg / g. When incorporated into a consumable, the composition may be present at about 5% w / w to about 30% w / w meaning that these amounts will be adjusted accordingly based on the total weight of the consumable. In some examples, the composition may be present at about 5% w / w to about 20% w / w. In some examples, the composition may be present at about 5% w / w to about 15% w / w. For example, at an inclusion level of 10% w / wDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0165] of the composition, the consumable may comprise from about 0.000001 wt% to about 0.003 wt% of each C6 to C18 substituted pyridine which is not an alkaloid, or the total amount of C6 to C18 substituted pyridine which is not alkaloid is about 0.00001 wt% to about 0.005 wt%, based on the total weight of the consumable.

[0166] Sesquiterpenes

[0167] In some examples, the composition comprises at least one sesquiterpene. Sesquiterpenes are a class of terpenes that consist of three isoprene units and often have the molecular formula C15H24. Sesquiterpenes may be cyclic. In some examples, the at least one sesquiterpene in the composition of the present disclosure is a cyclic sesquiterpene. The sesquiterpene may be defined by its molecular weight: from about 200 g / mol to about 300 g / mol.

[0168] In some examples, the sesquiterpene may be selected from calamenene, alpha-muurolene, r-cadinene, viridiflorene, longifolene, nootkatone, beta-bisabolol, cedrol, nerolidol, santalol, beta-bisabolene, beta-cedrene, beta-humulene, alpha-cyperone, cyperotundone, 3,7-dimethyl-10-(propan-2-ylidene)cyclodeca-3,7-dienone, solavetivone, alantolactone, bergamontene, neophytadiene, guai-1(5)-en-11-ol:acetate, and combinations thereof.

[0169] In some examples, each sesquiterpene is present in the composition in an amount from about 0.5 pg / g to about 550 pg / g. In some examples, each sesquiterpene is present in an amount from about 2 pg / g to about 250 pg / g. In some examples, the total amount of sesquiterpene in the composition is from about 20 pg / g to about 600 pg / g. In some examples, the total amount of sesquiterpene in the composition is from about 20 pg / g to about 300 pg / g. When incorporated into a consumable, the composition may be present at about 5% w / w to about 30% w / w meaning that these amounts will be adjusted accordingly. In some examples, the composition may be present at about 5% w / w to about 20% w / w. In some examples, the composition may be present at about 5% w / w to about 15% w / w. For example, at an inclusion level of 10% w / w for the composition, the consumable may include each sesquiterpene in an amount of from about 0.00005 wt% to about 0.055 wt%, or from about 0.0002 wt% to about 0.025 wt%. The total amount of sesquiterpene may be from about 0.0002 wt% to about 0.06 wt%, or from about 0.0002 to about 0.03 wt%, based on the total weight of the consumable.

[0170] Terpene Alcohol

[0171] The composition of the present disclosure may include at least one terpene alcohol. Terpene alcohols are a type of terpenoid; they are naturally occurring compounds found in various plants, fruits, and essential oils. Some examples include linalool (found in lavender), terpineolDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0172] (found in lilacs) and geraniol (found in roses). Specifically, terpene alcohols are terpenes that include one or more alcohol / hydroxyl functional groups. In some examples, the terpene alcohol is defined by its molecular weight; the molecular weight of each terpene alcohol may be from about 120 g / mol to about 320 g / mol.

[0173] In some examples, the terpene alcohol is selected from linalool, geranyl linalool, isophytol, dihydrolinalool, phytol, sclareol, 2-[5-methyl-5-vinyltetrahydro-2-furanyl]-2-propanol, a b 2,7,11 Cembratrienodiol 4,6 diol, labdenediol, nerolidol, and combinations thereof. In some examples, the terpene alcohol is not menthol.

[0174] In some examples, each terpene alcohol is present in the composition an amount from about 0.1 pg / g to about 100 pg / g. In some examples, each terpene alcohol is present in the composition in an amount from about 1 pg / g to about 60 pg / g. In some examples, the total amount of terpene alcohol in the composition is from about 1 pg / g to about 150 pg / g. In some examples, the total amount of terpene alcohol in the composition is from about 5 pg / g to about 100 pg / g. When incorporated into a consumable, the composition may be present at about 5% w / w to about 30% w / w meaning that these amounts will be adjusted accordingly. In some examples, the composition may be present at about 5% w / w to about 20% w / w. In some examples, the composition may be present at about 5% w / w to about 15% w / w. For example, at an inclusion level of 10% w / w for the composition, the consumable may include each terpene alcohol in an amount of from about 0.00001 wt% to about 0.01 wt%, or from about 0.0001 wt% to about 0.006 wt%. The total amount of terpene alcohol may be from about 0.0001 wt% to about 0.015 wt%, based on the total weight of the consumable.

[0175] Fatty Acids

[0176] In some examples, the composition of the present disclosure includes at least one C5 to C24 fatty acid. The C5 to C24 fatty acid is not particularly limited. In some examples, the C5 to C24 fatty acid may be defined by its molecular weight being from about 100 g / mol to about 300 g / mol. In some examples, the C5 to C24 fatty acid may be saturated or unsaturated.

[0177] In some examples, the at least one C5 to C24 fatty acid may be selected from: butanoic acid 2-methylbutanoic acid; 3-methylvaleric acid; Pentanoic acid, 3-methyl-; valeric acid; isovaleric acid; hexanoic acid; hexanoic acid, 2-methyl-; heptanoic acid; propanoic acid; propanoic acid, 2-methyl-; decanoic acid; dodecanoic acid; levulinic acid; octanoic acid; pelargonic acid; tetradecanoic acid; pentadecanoic acid; palmitic acid; stearic acid; octadecatrienoic acid; linoleic acid; linolenic acid; elaidic acid; 24-Hydroxytetracosanoic acid; and combinations thereof. In some examples, the C5 to C24 fatty acid may be selected from 2-methylbutanoicDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0178] acid; 3-methylvaleric acid; valeric acid; isovaleric acid; Pentanoic acid, 3-methyl-; perlargonic acid; tetradecanoic acid; pentadecanoic acid; palmitic acid; linolenic acid; octadecatrienoic acid; linolenic acid; eladic acid; and combinations thereof.

[0179] When present, each C5 to C24 fatty acid may be present in the composition in an amount of from about 0.1 pg / g to about 300 pg / g. When incorporated into a consumable, the composition may be present at about 5% w / w to about 30% w / w meaning that these amounts will be adjusted accordingly, based on the total weight of the consumable. In some examples, the composition may be present at about 5% w / w to about 20% w / w. In some examples, the composition may be present at about 5% w / w to about 15% w / w. For example, at an inclusion level of 10% w / w of the composition, the consumable may include about 0.00001 wt% to about 0.03 wt% of each C5 to C24 fatty acid, based on the total weight of the consumable.

[0180] In some examples, the total amount of C5 to C24 fatty acid may be about 10 to about 500 pg / g. When incorporated into a consumable, the composition may be present at about 5% w / w to about 30% w / w meaning that these amounts will be adjusted accordingly, based on the total weight of the consumable. In some examples, the composition may be present at about 5% w / w to about 20% w / w. In some examples, the composition may be present at about 5% w / w to about 15% w / w. For example, at an inclusion level of 10% w / w of the composition, the consumable may include about 0.001 wt% to about 0.05 wt% of each C5 to C24 fatty acid, based on the total weight of the consumable.

[0181] Preferred Examples of Compound Groups

[0182] In some examples, the composition includes the following compound groups (a) to (c):

[0183] (a) at least one C6 to C18 substituted pyrazine, wherein the substituents are selected from C1-6 alkyl groups, C2-6 alkenyl groups, C2-6 ketones, C1-6 alkoxy groups, hydroxyl groups, sulfhydryl groups, and combinations thereof;

[0184] (b) at least one C8 to C18 aromatic ester selected from benzoates, phenylacetates, acetates, cinnamates, phthalates, pentanoates, isovalerates, acetoxytoluenes, anisates, biphenylcarboxlates, and combinations thereof; and

[0185] (c) at least one C5 to C24 fatty acid.

[0186] In some examples, the composition includes the following compound groups (a) to (c):DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0187] (a) at least two C6 to C18 substituted pyrazines selected from: 2-methylpyrazine; 2,3-dimethylpyrazine; 2,5-dimethyl pyrazine; 2-ethylpyrazine; acetyl pyrazine; 2-ethyl-6-methylpyrazine; 2-methoxy-3-methylpyrazine; 2-methyl-3-methylsulfanylpyrazine; 1-pyrazin-2-ylethanone; 2,6-dimethylpyrazine; 2-ethenyl-pyrazine; 2-methyl-3-butyl-pyrazine; and combinations thereof; and a C6 to C18 substituted pyridine which is an alkaloid;

[0188] (b) at least one C8 to C18 aromatic ester selected from: methyl benzoate, ethyl benzoate, methyl phenylacetate, ethyl phenylacetate, methyl cinnamate, isoamyl cinnamate, benzyl pentanoate, benzyl benzoate, cyclohexyl butyl phthalate, dibutyl phthalate, bis(2-ethylhexyl)benzene-1,3-dicarboxylate, methyl 3,4,5-trihydroxybenzoate, and combinations thereof;

[0189] (c) at least one C2 to C24 carboxylic acid selected from: benzoic acid, acetic acid, phenylacetic acid, or one or more C5 to C24 fatty acids optionally selected from 2-methylbutanoic acid; 3-methylvaleric acid; Pentanoic acid, 3-methyl-; valeric acid; decanoic acid; dodecanoic acid; octanoic acid; pelargonic acid; tetradecanoic acid; pentadecanoic acid; palmitic acid; stearic acid; octadecatrienoic acid; linolenic acid; elaidic acid; and combinations thereof.

[0190] In some examples, the composition includes the following compound groups (a) to (c):

[0191] (a) at least two C6 to C18 substituted pyrazines selected from 2-methylpyrazine; 2,3-dimethylpyrazine; 2,5-dimethyl pyrazine; 2-ethylpyrazine; acetyl pyrazine; 2-ethyl-6-methylpyrazine; 2-methoxy-3-methylpyrazine; 2-methyl-3-methylsulfanylpyrazine; 1-pyrazin-2-ylethanone; 2,6-dimethylpyrazine; 2-ethenyl-pyrazine; 2-methyl-3-butyl-pyrazine; and combinations thereof;

[0192] (b) at least one sesquiterpene which is neophytadiene, or at least one terpene alcohol selected from linalool, isophytol, phytol, sclareol, and combinations thereof; and

[0193] (c) at least one C5 to C24 fatty acid optionally selected from 2-methylbutanoic acid; 3-methylvaleric acid; Pentanoic acid, 3-methyl-; valeric acid; decanoic acid; dodecanoic acid; octanoic acid; pelargonic acid; tetradecanoic acid; pentadecanoic acid; palmitic acid; stearic acid; octadecatrienoic acid; linolenic acid; elaidic acid; and combinations thereof.

[0194] In some examples, the composition includes the following compound groups (a) to (c):

[0195] (a) at least one C6 to C18 substituted pyridine selected from n-phenylpyridine-3-carboxamide; 1-(5-methylpyridin-3-yl)ethanone; thionicotinic acid; 3-(2,3-dihydro-1h-pyrrol-5-yl)pyridine; 3-[1,2,3,6-tetrahydropyridin-2-yl]pyridine; 3-phenylpyridine; 2-(pyridin-2-ylmethyl)pyridine; 3-DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0196] methyl-2-phenylpyridine; 1-pyridin-3-ylethanone; 2-(3-pyridinyl)-2-pyrroline; and combinations thereof;

[0197] (b) at least one sesquiterpene which is neophytadiene, or at least one terpene alcohol selected from linalool, isophytol, phytol, sclareol, and combinations thereof; and

[0198] (c) at least one C5 to C24 fatty acid optionally selected from 2-methylbutanoic acid; 3-methylvaleric acid; Pentanoic acid, 3-methyl-; valeric acid; decanoic acid; dodecanoic acid; octanoic acid; pelargonic acid; tetradecanoic acid; pentadecanoic acid; palmitic acid; stearic acid; octadecatrienoic acid; linolenic acid; elaidic acid; and combinations thereof.

[0199] In some examples, the composition includes the following compound groups (a) to (c):

[0200] (a) at least one C6 to C18 substituted pyridine selected from n-phenylpyridine-3-carboxamide; 1-(5-methylpyridin-3-yl)ethanone; thionicotinic acid; 3-(2,3-dihydro-1h-pyrrol-5-yl)pyridine; 3-[1,2,3,6-tetrahydropyridin-2-yl]pyridine; 3-phenylpyridine; 2-(pyridin-2-ylmethyl)pyridine; 3-methyl-2-phenylpyridine; 1-pyridin-3-ylethanone; 2-(3-pyridinyl)-2-pyrroline; and combinations thereof; and a C6 to C18 substituted pyridine which is an alkaloid;

[0201] (b) at least one C8 to C18 aromatic ester selected from: methyl benzoate, methyl phenylacetate, ethyl phenylacetate, methyl cinnamate, isoamyl cinnamate, benzyl pentanoate, benzyl benzoate, cyclohexyl butyl phthalate, dibutyl phthalate, bis(2-ethylhexyl)benzene-1,3-dicarboxylate, methyl 3,4,5-trihydroxybenzoate, and combinations thereof.; and

[0202] (c) at least one C2 to C24 carboxylic acid selected from: benzoic acid, acetic acid, phenylacetic acid, or a combination thereof, and one or more C5 to C24 fatty acids optionally selected from 2-methylbutanoic acid; 3-methylvaleric acid; Pentanoic acid, 3-methyl-; valeric acid; decanoic acid; dodecanoic acid; octanoic acid; pelargonic acid; tetradecanoic acid; pentadecanoic acid; palmitic acid; stearic acid; octadecatrienoic acid; linolenic acid; elaidic acid; and combinations thereof.

[0203] In some examples, the composition further includes compounds from each of the three groups. The groups are: (1) C7 to C18 aromatic alcohols; (2) C3 to C24 aliphatic esters and C8 to C18 aromatic esters; and (3) C4 to C18 lactones. In some examples, the composition further includes at least one compound from (4) phenol and C7 to C18 substituted phenols. Each group will now be discussed but the skilled person will understand that the examples presented for each group may be combined according to the above.

[0204] Group 1: C7 to C18 aromatic alcoholsDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0205] In some examples, the composition further comprises at least one C7 to C18 aromatic alcohol. The C7 to C18 aromatic alcohol may be defined by its molecular weight being from about 100 g / mol and about 200 g / mol. In some examples, the at least one aromatic alcohol is a C7 to C18 aromatic alcohol, wherein a benzene ring is substituted by one or more alkyl, alkenyl, and hydroxyl groups, or a combination thereof. In some examples, the at least one aromatic alcohol is selected from benzyl alcohol, phenylethanol, phenylmethylcarbinol, 1-phenylpropane-1,2-diol, 1-phenyl-2-butanol, Benzenemethanol, α-dimethyl-, 4-hydroxybenzyl alcohol, Vanillyl alcohol, cinnamyl alcohol, and combinations thereof. In some examples, the at least one aromatic alcohol includes phenylethanol.

[0206] In some examples, each C7 to C18 aromatic alcohol is present in the composition in an amount of from about 0.5 pg / g to about 100 pg / g. In some examples, each C7 to C18 aromatic alcohol is present in an amount of from about 0.5 pg / g to about 75 pg / g. When incorporated into a consumable, the composition may be present at about 5% w / w to about 30% w / w meaning that these amounts will be adjusted accordingly, based on the total weight of the consumable. In some examples, the composition may be present at about 5% w / w to about 20% w / w. In some examples, the composition may be present at about 5% w / w to about 15% w / w. For example, at an inclusion level of 10% w / w of the composition, each C7 to C18 aromatic alcohol may be present in the consumable in an amount of about 0.0005 wt% to about 0.01 wt%, or about 0.0005 wt% to about 0.0075 wt%, based on the total weight of the consumable.

[0207] In some examples, the total amount of C7 to C18 aromatic alcohol is from about 0.5 pg / g to about 100 pg / g. In some examples, the total amount of C7 to C18 aromatic alcohol is from about 0.5 pg / g to about 75 pg / g. When incorporated into a consumable, the composition may be present at about 5% w / w to about 30% w / w meaning that these amounts will be adjusted accordingly, based on the total weight of the consumable. In some examples, the composition may be present at about 5% w / w to about 20% w / w. In some examples, the composition may be present at about 5% w / w to about 15% w / w. For example, at an inclusion level of 10% w / w of the composition, the total amount of C7 to C18 aromatic alcohol in the consumable may be about 0.0005 wt% to about 0.01 wt%, or about 0.0005 wt% to about 0.0075 wt%, based on the total weight of the consumable.

[0208] Group (2): C3 to C24 aliphatic esters and C8 to C18 aromatic esters

[0209] In some examples, the additional compounds include one or more C3 to C24 aliphatic esters and / or one or more C8 to C18 aromatic esters (if not already present in the above-defined preferred compound groups). The one or more C3 to C24 aliphatic ester, which may be a fattyDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0210] acid ester, may be defined by its molecular weight which may be from about 100 g / mol to about 350 g / mol.

[0211] The C3 to C24 aliphatic esters may be fatty acid esters such as butyrates, hexanoates, octanoates, decanoates, laurates, tetradecanoates, palmitates, pentadecanoates, linoleates, linolenates, stearates, or a docosahexanoic acid ester. In some examples, the one or more C3 to C24 aliphatic ester may be selected from ethyl butyrate, methyl butyrate, methyl hexanoate, ethyl hexanoate, methyl octanoate, ethyl octanoate, methyl decanoate, ethyl decanoate, methyl laurate, ethyl laurate, methyl tetradecanoate, ethyl tetradecanoate, methyl palmitate, ethyl pentadecanoate, ethyl palmitate, methyl linoleate, ethyl linolenate, ethyl linoleate, ethyl stearate, methyl linolenate, docosahexanoic acid methyl ester, and combinations thereof. In some examples, the additional compounds therefore include one or more C3 to C24 aliphatic esters which are fatty acid esters.

[0212] In some examples, each C3 to C24 aliphatic ester, which is preferably a fatty acid ester, may be present in an amount of about 0.5 pg / g to about 150 pg / g. When incorporated into a consumable, the composition may be present at about 5% w / w to about 30% w / w meaning that these amounts will be adjusted accordingly. In some examples, the composition may be present at about 5% w / w to about 20% w / w. In some examples, the composition may be present at about 5% w / w to about 15% w / w. For example, an inclusion level of 10% w / w for the composition, means that each C3 to C24 aliphatic ester may be present in the consumable from about 0.00005 wt% to about 0.015 wt%, based on the total weight of the consumable.

[0213] In some examples, the total amount of C3 to C24 aliphatic esters, which are preferably fatty acid esters, may be from about 15 pg / g to about 300 pg / g. In preferred examples, the total amount of C3 to C24 fatty acid esters may be about 20 pg / g to about 250 pg / g. When incorporated into a consumable, the composition may be present at about 5% w / w to about 30% w / w meaning that these amounts will be adjusted accordingly, based on the total weight of the consumable. In some examples, the composition may be present at about 5% w / w to about 20% w / w. In some examples, the composition may be present at about 5% w / w to about 15% w / w. For example, at an inclusion level of 10% w / w of the composition, the consumable may include about 0.0015 wt% to about 0.03 wt% of C3 to C24 aliphatic esters, based on the total weight of the consumable. In preferred examples, the consumable may comprise about 0.002 wt% to about 0.025 wt% of C3 to C24 fatty acid esters; the fatty acid esters may be as defined above.

[0214] In some examples, the additional compounds comprise one or more C8 to C18 aromatic esters. In some examples, the additional compounds comprise one or more C3 to C24DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0215] aliphatic esters and one or more C8 to C18 aromatic esters. In some examples, the C8 to C18 aromatic esters may be defined by their molecular weight which may be from about 120 g / mol to about 350 g / mol. In some examples, the C7 / C8 to C18 aromatic esters may be selected from benzoates, phenylacetates, acetates, cinnamates, phthalates, pentanoates, isovalerates, acetoxytoluenes, anisates, biphenylcarboxlates, and combinations thereof. These ester compounds may include alkyl groups, alkenyl groups, aryl groups, hydroxyls, halo compounds, alkoxy groups, carboxyl groups, ether groups, and combinations thereof.

[0216] In some examples, the C8 to C18 aromatic ester may be selected from methyl benzoate, ethyl benzoate, methyl phenylacetate, ethyl phenylacetate, propyl phenylacetate, methyl cinnamate, ethyl cinnamate, isoamyl cinnamate, isobutyl benzoate, methyl 4-fluoro-3-methoxybenxoate, benzyl pentanoate, phenylethyl isovalerate, 2,5-diacetoxytoluene, 2,6-dimethoxyphenylacetate, methyl biphenyl-4-carboxylate, benzyl benzoate, benzyl acetate, isoeugenol acetate, ethyl anisate, phenethyl phenylacetate, diethylene glycol dibenzoate, cyclohexyl butyl phthalate, 2-hydroxyethyl benzoate; 2-chloroethyl benzoate; dibutyl phthalate; bis(2-ethylhexyl) benzene-1,3-dicarboxylate; Methyl 3,4,5-trihydroxybenzoate; (3-hydroxyphenyl) benzoate; and combinations thereof. In some examples, the C8 to C18 aromatic ester may be selected from methyl benzoate, methyl phenylacetate, ethyl phenylacetate, methyl cinnamate, isoamyl cinnamate, benzyl pentanoate, benzyl benzoate, cyclohexyl butyl phthalate, dibutyl phthalate, bis(2-ethylhexyl)benzene-1,3-dicarboxylate, methyl 3,4,5-trihydroxybenzoate, and combinations thereof.

[0217] In some examples, each C8 to C18 aromatic ester may be present in an amount of about 0.1 pg / g to about 20 pg / g. When incorporated into a consumable, the composition may be present at about 5% w / w to about 30% w / w meaning that these amounts will be adjusted accordingly. In some examples, the composition may be present at about 5% w / w to about 20% w / w. In some examples, the composition may be present at about 5% w / w to about 15% w / w. For example, an inclusion level of 10% w / w for the composition, means that each C8 to C18 aromatic ester may be present in the consumable from about 0.00001 wt% to about 0.002 wt%, based on the total weight of the consumable.

[0218] In some examples, the total amount of C8 to C18 aromatic esters may be from about 1 pg / g to about 50 pg / g. When incorporated into a consumable, the composition may be present at about 5% w / w to about 30% w / w meaning that these amounts will be adjusted accordingly, based on the total weight of the consumable. In some examples, the composition may be present at about 5% w / w to about 20% w / w. In some examples, the composition may be present at about 5% w / w to about 15% w / w. For example, at an inclusion level of 10% w / w ofDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0219] the composition, the consumable may include about 0.0001 wt% to about 0.005 wt% of C8 to C18 aromatic esters, based on the total weight of the consumable.

[0220] Group 3: C4 to C18 Lactones

[0221] In some examples, the additional compounds include at least one C4 to C18 lactone. The at least one C4 to C18 lactone may be defined by its molecular weight being from about 80 g / mol to about 350 g / mol.

[0222] In some examples, the at least one C4 to C18 lactone is selected from gamma-lactones, delta-lactones, coumarins, pyranones, furanones, carotenoid or terpenoid lactones, furanocoumarins, furocoumarins, and unsaturated lactones. In some examples, the at least one C4 to C18 lactone is selected from valerolactone, undecan-4-olide, dihydroactinidiolide, delta-Decalactone, sclareolide, butyrolactone, but-2-en-4-olide, caprolactone, dl-pantolactone, gamma-octanoic lactone, gamma-nonalactone, alpha-levantanolide, 6-pentyloxan-2-one, gamma-decanolactone, (2,6,6-trimethyl-2-hydroxycyclohexylidene)acetic acid lactone, dodecalactone, loliolide, 5-methoxypsoralen, 6-methoxyfuro[2,3-h]chromen-2-one, maltol (3-Hydroxy-2-methyl-4H-pyran-4-one), 2,3-dihydro-3,5-dihydroxy-6-methyl-4(h)-pyran-4-one, ethyl maltol (2-Ethyl-3-hydroxy-4H-pyran-4-one), 3,4-dihydroisocoumarin, coumarin, 3,4-dihydrocoumarin, 6-methylcoumarin, 6-hydroxy-4-methylcoumarin, 7-hydroxycoumarin, 7-ethoxycoumarin, scopoletin, esculetin, 3-amino-4,7-dihydroxycoumarin, 6-Ethyl-5,6-dihydro-2H-pyran-2-one, pantolactone, and combinations thereof.

[0223] In some examples, each C4 to C18 lactone is present in an amount of about 1 pg / g to about 300 pg / g. When incorporated into a consumable, the composition may be present at about 5% w / w to about 30% w / w meaning that these amounts will be adjusted accordingly. In some examples, the composition may be present at about 5% w / w to about 20% w / w. In some examples, the composition may be present at about 5% w / w to about 15% w / w. For example, an inclusion level of 10% w / w for the composition, means that each C4 to C18 lactone may be present in the consumable from about 0.0001 wt% to about 0.03 wt%, based on the total weight of the consumable.

[0224] In some examples, the total amount of C4 to C18 lactones may be from about 10 pg / g to about 500 pg / g. For example, when the C4 to C18 lactones include a C4 to C18 alkyl lactone as defined above. When incorporated into a consumable, the composition may be present at about 5% w / w to about 30% w / w meaning that these amounts will be adjusted accordingly, based on the total weight of the consumable. In some examples, the composition may be present at about 5% w / w to about 20% w / w. In some examples, the composition may be present at about 5% w / w to about 15% w / w. For example, at an inclusion level of 10% w / w ofDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0225] the composition, the consumable may include about 0.001 wt% to about 0.05 wt% of C4 to C18 lactones.

[0226] Group (4): Phenol and C7 to C18 Substituted Phenols

[0227] In some examples, the additional compounds may further include phenol or the composition may be substantially free or free of phenol.

[0228] In some examples, the additional compounds include at least one C7 to C18 substituted phenol. The at least one C7 to C18 substituted phenol may be defined by its molecular weight being from about 100 g / mol to about 250 g / mol.

[0229] The C7 to C18 substituted phenols include one or more substituents which may be selected from alkyls, alkenyls, alkoxy groups, pyrrolidine, phenyls, acetals, hydroxyl groups (i.e. more than one hydroxyl group may be present), carboxyls (e.g. ketones, aldehydes, esters), and halogens (e.g. fluorine). In some examples, the C7 to C18 substituted phenol includes one or more substituents selected from alkyl groups, alkenyl groups, acetals, phenyls, alkoxy groups, esters, ketones, aldehydes, pyrrolidine, fluorine, and combinations thereof. In some examples, the C7 to C18 substituted phenol includes one or more substituents selected from alkyl groups, alkenyl groups, alkoxy groups, and combinations thereof. As noted above, aromatic aldehydes / acetals may simultaneously be C7 to C18 substituted phenols but if classified under one compound group, the skilled person will understand that the compound will not simultaneously be classified under another compound group. For example, if ethyl vanillin is considered an aromatic aldehyde and a C7 to C18 aromatic alcohol is present, then the composition will include another compound, e.g. 2,4-di-tert-butylphenol, as the C7 to C18 substituted phenol.

[0230] In some examples, the composition is substantially free of polyphenols.

[0231] In some examples, the composition further comprises a C7 to C18 substituted monophenol. The substituents are as defined above.

[0232] In some examples, the composition includes at least one C7 to C18 substituted phenol selected from: 2-methoxyphenol, 2-pyrrolidin-1-ylphenol, 2,3-dimethoxyphenol, 3-cyclohexylphenol, 4-ethyl-2-methoxyphenol, 4-(2-hydroxyethyl)-2-methoxyphenol, 2,6-dimethoxy-4-methylphenol, biphenyl-2-ol, 4-Ethyl-2,6-dimethoxyphenol, 4-allyl-2,6-dimethoxyphenol, 2,4-di-tert-butylphenol, 2,6-dicyclohexylphenol, 2,6-di-tert-butyl-4-methylphenol, 2-ethoxy-5-(1-propenyl)phenol, 2-methoxy-4-(4-methyl-1,3-dioxolan-2-yl)phenol, 2,4-dihydroxy-6-methylbenzaldehyde, 4-Hydroxy-3-methoxybenzaldehyde, MethylDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0233] 3,4,5-trihydroxybenzoate, (3-hydroxyphenyl) benzoate, 1-(2-Hydroxy-4-methoxyphenyl)ethan-1-one, 1-(2,3-dihydroxy-4-methoxyphenyl)ethanone, 1-(4-Hydroxy-3,5-dimethoxyphenyl)ethan-1-one, 1-(2-hydroxy-4,5-dimethoxyphenyl)ethanone, coniferyl aldehyde, 1-(4-hydroxy-3-methoxyphenyl)propan-2-one, 2-hydroxy-4-methoxybenzaldehyde, ethyl vanillin, 2-fluoro-3-hydroxy-4-methoxybenzaldehyde, 1-(2-hydroxy-3-phenylphenyl)ethanone (2-hydroxy-3-phenylacetophenone), ethyl 4-hydroxy-3-methoxybenzoate, 4'-hydroxyacetophenone, p-cresol, 2,4-dimethylphenol, 3,4-dimethylphenol, 3,5-dimethylphenol, 2-ethylphenol, 4-ethylphenol, 2,6-dimethoxyphenol, 1-(2-hydroxy-5-methylphenyl)ethenone, 5-ethenyl-2-methoxy-phenol, and combinations thereof.

[0234] In some examples, each C7 to C18 substituted phenol is present in an amount of from about 0.1 pg / g to about 600 pg / g. When incorporated into a consumable, the composition may be present at about 5% w / w to about 30% w / w meaning that these amounts will be adjusted accordingly, based on the total weight of the consumable. In some examples, the composition may be present at about 5% w / w to about 20% w / w. In some examples, the composition may be present at about 5% w / w to about 15% w / w. For example, at an inclusion level of 10% w / w of the composition, the consumable may include about 0.00001 wt% to about 0.06 wt% of each C7 to C18 substituted phenol, based on the total weight of the consumable.

[0235] In some examples, each C7 to C18 substituted phenol is present in an amount of from 0.1 pg / g to about 100 pg / g. When incorporated into a consumable, the composition may be present at about 5% w / w to about 30% w / w meaning that these amounts will be adjusted accordingly, based on the total weight of the consumable. In some examples, the composition may be present at about 5% w / w to about 20% w / w. In some examples, the composition may be present at about 5% w / w to about 15% w / w. For example, at an inclusion level of 10% w / w of the composition, the consumable may include about 0.00001 wt% to about 0.01 wt% of each C7 to C18 substituted phenol, based on the total weight of the consumable.

[0236] In some examples, the total amount of C7 to C18 substituted phenol is from about 10 to about 600 pg / g. When incorporated into a consumable, the composition may be present at about 5% w / w to about 30% w / w meaning that these amounts will be adjusted accordingly, based on the total weight of the consumable. In some examples, the composition may be present at about 5% w / w to about 20% w / w. In some examples, the composition may be present at about 5% w / w to about 15% w / w. For example, at an inclusion level of 10% w / w of the composition, the consumable may include about 0.001 wt% to about 0.06 wt% of C7 to C18 substituted phenol, based on the total weight of the consumable.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0237] In some examples, the total amount of C7 to C18 substituted phenol is from about 10 to about 300 pg / g. When incorporated into a consumable, the composition may be present at about 5% w / w to about 30% w / w meaning that these amounts will be adjusted accordingly, based on the total weight of the consumable. In some examples, the composition may be present at about 5% w / w to about 20% w / w. In some examples, the composition may be present at about 5% w / w to about 15% w / w. For example, at an inclusion level of 10% w / w of the composition, the consumable may include about 0.001 wt% to about 0.03 wt% of C7 to C18 substituted phenol, based on the total weight of the consumable.

[0238] In some examples, the composition further comprises one or more ketone. The ketone is not limited but in some examples the composition comprises two or more ketones. Such ketones may include at least one cyclic unsaturated ketone, e.g. 2-cyclohexen-1-one, 4-(3-hydroxy-1-butenyl)-3,5,5-trimethyl-; 2-cyclohexen-1-one, 4-(3-hydroxybutyl)-3,5,5-trimethyl-; 2-hydroxy-3-methyl-2-cyclopentenone; 2-cyclopenten-1-one, 3-ethyl-2-hydroxy-; 2-cyclopenten-1-one, 2-hydroxy-, 2-cyclopenten-1-one, 2-ethyl-3-hydroxy, 2,6,6-Trimethyl-2-cyclohexene-1,4-dione; furaneol; or combinations thereof, at least one acyclic unsaturated ketone, e.g. 6,8-nonadien-2-one, 8-methyl-5-(1-methylethyl)-; geranyl acetone; 5,9,13-pentadecatrien-2-one, 6, 10, 14-trimethyl-; 2-pentadecanone, 6, 10, 14-trimethyl-; or combinations thereof, and / or at least one heteroaromatic ketone or aromatic ketone, e.g. dibenzylketone, 1-(5-methylpyridin- 3-yl)ethanone; 1-pyridin-3-ylethanone; 2-acetylpyrrole; Ethanone, 1-(1H-pyrrol-2-yl)-; 1-Propanone, 1-(4-methyl-2-pyridinyl)-; Ethanone, 1-(2-hydroxy-5-methylphenyl)-; Ethanone, 1-(4-methylphenyl)-; 6-Ethyl-3-hydroxy-2-methyl-4-pyrone; or a combination thereof.

[0239] In some examples, the molecular weight of the ketone is from about 85 g / mol to about 300 g / mol.

[0240] In some examples, the total amount of the one or more ketones is from about 20 pg / g to about 850 pg / g. When incorporated into a consumable, the composition may be present at about 5% w / w to about 30% w / w meaning that these amounts will be adjusted accordingly, based on the total weight of the consumable. For example, at an inclusion level of 10% w / w of the composition, the total amount of the one or more ketones may be about 0.002 wt% to about 0.085 wt%, based on the total weight of the consumable.

[0241] In some examples, when present the total amount of the one or more ketones may be from 0.1 pg / g to about 850 pg / g, such as from about 20 pg / g to about 850 pg / g.

[0242] In some examples, the total amount of the one or more ketones is from about 20 pg / g to about 350 pg / g. When incorporated into a consumable, the composition may be present at about 5% w / w to about 30% w / w meaning that these amounts will be adjusted accordingly, basedDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0243] on the total weight of the consumable. In some examples, the composition may be present at about 5% w / w to about 20% w / w. In some examples, the composition may be present at about 5% w / w to about 15% w / w. For example, at an inclusion level of 10% w / w of the composition, the total amount of the one or more ketones may be about 0.002 wt% to about 0.035 wt%, based on the total weight of the consumable.

[0244] In some examples, the composition further includes at least one alkaloid selected from nicotine, myosmine, cotinine, caffeine, nicotyrine, N’propylnornicotine, and combinations thereof.

[0245] In some examples, the composition is nicotine-free.

[0246] In some examples, the composition is substantially free of ethyl vanillin. In some examples, the composition is free of ethyl vanillin.

[0247] In some examples, the extract composition comprises at least one aliphatic aldehyde. When present, the total amount of the one or more aliphatic aldehydes may be from 0.1 pg / g to about 100 pg / g.

[0248] In some examples, the extract composition comprises at least one C7 to C18 aromatic aldehyde; an aromatic aldehyde is an aromatic group which is substituted with at least one aldehyde group. The aromatic acetal / aldehyde may include one or more further substituents; such substituents are not typically limited. In some examples the one or more further substituents do not include hydroxyl groups. In some examples, the C7 to C18 aromatic aldehyde is defined by their molecular weight; the molecular weight of each C7 to C18 aromatic aldehyde may from about 100 g / mol to about 250 g / mol.

[0249] In some examples, when present the total amount of the one or more aromatic aldehydes may be from 0.1 pg / g to about 10 pg / g.

[0250] In some examples, the composition further comprises a pyranone derivative, such as 2h-pyran-2-one, 6-ethyl-5,6-dihydro-; 3-hydroxy-2-methyl-4h-pyran-4-one; 2-ethyl-3-hydroxy-4h-pyran-4-one; or a combination thereof. In some examples, the composition comprises 2h-pyran-2-one, 6-ethyl-5,6-di hydro-.

[0251] In some examples the formulation comprises the composition in an amount of at least about 1% by weight, such as at least about 5 wt% by weight, preferably at least about 10 wt% by weight. The composition may be present in the formulation in an amount of no greater than about 25% by weight, such as no greater than about 20% by weight, preferably no greater than about 15 wt% by weight. In some examples the composition may be present in theDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0252] formulation in an amount of from about 1% by weight to about 25% by weight, such as from about 5 wt% by weight to about 20% by weight, preferably from about 10% by weight to about 15% by weight.

[0253] The aerosolisable formulation may take various forms, provided that the formulation is capable of generating aerosol, for example when heated, irradiated or energized in any other way, including a semi-solid (such as a gel), a liquid or a solid, which may or may not contain an active substance and / or flavourants as defined herein. The aerosol-generating material may comprise one or more active substances and / or flavours, one or more aerosol-former materials, and optionally one or more other functional material.

[0254] In some examples, the aerosolisable formulation is a liquid. In some examples the formulation is a liquid and comprises about 1% to about 25% by weight of the composition, about 50 to about 99% by weight of the aerosol-former material, and optionally nicotine, such as about 5 wt% by weight to about 20% by weight of the composition, about 60% to about 98% by weight of the aerosol-former material, and optionally nicotine, preferably about 10% by weight to about 15% by weight of the composition, about 70% to about 95% by weight of the aerosolformer material, and optionally nicotine.

[0255] Nicotine may be provided in any suitable amount depending on the desired dosage when the formulation is aerosolised and inhaled by the user. Nicotine may be included in the composition even if it is already present in the composition. In some examples nicotine is present in an amount of no greater than about 6 wt% based on the total weight of the formulation. In some examples nicotine is present in an amount of from about 0.1 to about 6 wt% based on the total weight of the formulation, such as from about 0.5 to about 6 wt% based on the total weight of the formulation, preferably about 0.5 to about 5 wt% based on the total weight of the formulation.

[0256] In some examples the aerosolisable formulation is a liquid and may comprise about 1% to about 25% by weight of the composition, where the composition is defined according to the examples above, about 50 to about 99 wt% of the aerosol-former material, and about 0.1 to about 6 wt% of nicotine.

[0257] In some examples the formulation may contain one or more acids in addition to nicotine (as the active agent). In some examples, the one or more acids may be one or more organic acids. In some examples, the one or more acids may be one or more organic acids selected from the group consisting of benzoic acid, levulinic acid, malic acid, maleic acid, fumaric acid, citric acid, lactic acid, acetic acid, succinic acid, and mixtures thereof. When included in theDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0258] formulation in combination with nicotine, the one or more acids may provide a formulation in which the nicotine is at least partially in protonated (such as monoprotonated and / or di protonated) form.

[0259] In some examples, the aerosolisable formulation / aerosol-generating material may be an extruded material or in the form of strands or strips. In some examples there is provided an aerosol generating material / system comprising the composition as defined herein, an aerosol former material, one or more binders, and optionally a botanical material. Optionally a filler may also be present. Optionally, a solvent, such as water, is also present and one or more other components of the aerosol-generating material may or may not be soluble in the solvent.

[0260] The aerosol-generating material may comprise or be in the form of an aerosol-generating film. The aerosol-generating film may comprise a binder, such as a gelling agent, and an aerosol former. Optionally, a substance to be delivered and / or filler may also be present. The aerosolgenerating film may have a thickness of about 0.015 mm to about 1 mm. For example, the thickness may be in the range of about 0.05 mm, 0.1 mm or 0.15 mm to about 0.5 mm or 0.3 mm. The aerosol-generating film may be continuous. For example, the film may comprise or be a continuous sheet of material. The sheet may be in the form of a wrapper; it may be gathered to form a gathered sheet or it may be shredded to form a shredded sheet. The shredded sheet may comprise one or more strands or strips of aerosol-generating material.

[0261] The aerosol-generating film may be discontinuous. For example, the aerosol-generating film may comprise one or more discrete portions or regions of aerosol-generating material, such as dots, stripes or lines, which may be supported on a support. In such examples, the support may be planar or non-planar.

[0262] The aerosol-generating film may be formed by combining a binder, such as a gelling agent, with a solvent, such as water, an aerosol-former and one or more other components, such as one or more substances to be delivered, to form a slurry and then heating the slurry to volatilise at least some of the solvent to form the aerosol-generating film. The slurry may be heated to remove at least about 60 wt%, 70 wt%, 80 wt%, 85 wt% or 90 wt% of the solvent.

[0263] The aerosol-generating material may comprise or be an “amorphous solid”. In some examples, the aerosol-generating material comprises an aerosol-generating film that is an amorphous solid. The amorphous solid may be a “monolithic solid”. The amorphous solid may be substantially non-fibrous. In some examples, the amorphous solid may be a dried gel. The amorphous solid is a solid material that may retain some fluid, such as liquid, within it. InDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0264] some examples, the amorphous solid may, for example, comprise from about 50wt%, 60wt% or 70wt% of amorphous solid, to about 90wt%, 95wt% or 100wt% of amorphous solid.

[0265] In some examples, the binder consists of one or more gelling agent(s). Suitably, the aerosolisable formulation or aerosol generating system comprises from about 2 wt% to about 80 wt% binder(s), for example from about 5 wt%, 7 wt%, 10 wt%, 15 wt%, 17 wt%, 20 wt%, or 25 wt% to about 70 wt%, 60 wt%, 50 wt%, 45 wt%, 40 wt%, 35 wt% or 30 wt% of one or more binders (all calculated on a dry weight basis). For example, the aerosolisable formulation or aerosol generating system may comprise about 5-70 wt%, 7-60 wt%, 10-50 wt%, 15-45 wt%, 17-40 wt%, 20-35 wt% or 25-30 wt% of the binder(s).

[0266] In some examples, the one or more binders comprises one or more gelling agent(s). In some examples, the one or more binders consist of one or more gelling agent(s). In some examples, the gelling agent comprises a hydrocolloid.

[0267] In some examples, the one or more binders comprises (or is) one or more compounds selected from polysaccharide gelling agents, such as alginate, pectin, starch or a derivative thereof, cellulose or a derivative thereof, pullulan, carrageenan, agar and agarose; gelatin; gums, such as xanthan gum, guar gum and acacia gum; silica or silicone compounds, such as PDMS and sodium silicate; clays, such as kaolin; and polyvinyl alcohol.

[0268] In some examples the one or more binders comprises (or is) one or more polysaccharide gelling agents. In some examples, the polysaccharide gelling agent is selected from alginate, pectin, starch or a derivative thereof, or cellulose or a derivative thereof. In some examples the polysaccharide gelling agent is selected from alginate and a cellulose derivative.

[0269] In some examples, the one or more binders is a polysaccharide gelling agent, optionally wherein the polysaccharide gelling agent is selected from alginate and a cellulose derivative. In some examples, the polysaccharide gelling agent is alginate. In some examples, the alginate is sodium alginate.

[0270] In some examples, the polysaccharide gelling agent is a cellulose derivative. Without wishing to be bound by theory, it is believed that such gelling agents do not react with calcium ions to form crosslinks. In some examples the binder is not crosslinked. The absence of crosslinks in the gelling agent may facilitate quicker delivery of the composition (and any optional additional active substances and / or flavours) from the aerosolisable formulation or aerosol generating system. Examples of cellulosic binders (also referred to herein as cellulosic gelling agents or cellulose derivatives) include, but are not limited to, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethylcellulose (CMC),DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0271] hydroxypropyl methylcellulose (HPMC), methyl cellulose, ethyl cellulose, cellulose acetate (CA), cellulose acetate butyrate (CAB), and cellulose acetate propionate (CAP). In some examples the cellulose or derivative thereof is selected from hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethylcellulose (CMC), hydroxypropyl methylcellulose (HPMC), methyl cellulose, ethyl cellulose, cellulose acetate (CA), cellulose acetate butyrate (CAB), and cellulose acetate propionate (CAP). In some examples, the cellulose derivative is CMC. For example, in some examples, the binder comprises (or is) one or more of alginate, pectin, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethylcellulose, pullulan, xanthan gum, guar gum, carrageenan, agarose, acacia gum, fumed silica, PDMS, sodium silicate, kaolin and polyvinyl alcohol.

[0272] In some examples, the binder comprises (or is) one or more of hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethylcellulose, guar gum, acacia gum, alginate and / or pectin. In some cases, the binder comprises (or is) alginate and / or pectin, and may be combined with a setting agent (such as a calcium source) during formation of the aerosolisable formulation or aerosol generating system. In some cases, the binder may comprise a calcium-crosslinked alginate and / or a calcium-crosslinked pectin. In some examples, the binder comprises (or is) alginate, optionally wherein the alginate is present in the aerosolisable formulation in an amount of from about 5-70 wt%, 7-60 wt%, 10-50 wt%, or 15-45 wt%, of the aerosolisable formulation or aerosol generating system (calculated on a dry weight basis). In some examples, alginate is the only binder present in the aerosolisable formulation / aerosol generating system. In other examples, the binder comprises alginate and at least one further binder, such as pectin. In particular examples, the binder is carboxymethylcellulose, optionally wherein the carboxymethylcellulose (CMC) is present in an amount of about 2-80 wt%, for example about 5-70 wt%, 10-60 wt%, 15-50 wt%, 17-45 wt%, 20-40 wt% or about 30 wt%. In some examples, CMC is the only binder present in the aerosolisable formulation / aerosol generating system.

[0273] The aerosolisable formulation or aerosol generating material may further comprise a filler. Use of a filler may help to reduce tackiness of the aerosolisable formulation / aerosol generating material, for example if high levels of aerosol-former material are present. Suitably, the aerosolisable formulation / aerosol generating material comprises from about 2 wt% to about 60 wt% binder and any optional filler. In some examples, filler is present in an amount of less than about 50 wt% of a filler, such as from about 1 wt% to 50 wt%, or 5 wt% to 40 wt%, or 5 wt% to 30 wt%, or 10 wt% to 20 wt%. In other examples, filler is present in an amount of less than 20 wt%, suitably less than 10 wt% or less than 5 wt%. In some cases, the aerosolisable formulation comprises less than 1 wt% of a filler, and in some cases, comprises no filler. TheDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0274] filler, if present, may comprise one or more inorganic filler materials, such as calcium carbonate, perlite, vermiculite, diatomaceous earth, colloidal silica, magnesium oxide, magnesium sulphate, magnesium carbonate, and suitable inorganic sorbents, such as molecular sieves. The filler may comprise one or more organic filler materials such as wood pulp; tobacco pulp; hemp fibre; starch and starch derivatives, such as maltodextrin; chitosan; and cellulose and cellulose derivatives, such as ground cellulose, microcrystalline cellulose and nanocrystalline cellulose. In particular cases, the aerosolisable formulation comprises no calcium carbonate such as chalk.

[0275] In particular examples which include filler, the filler is fibrous. For example, the filler may be a fibrous organic filler material such as wood pulp, tobacco pulp, hemp fibre, cellulose or cellulose derivatives. In some examples, the fibrous organic filler material may be wood pulp, hemp fibre, cellulose or cellulose derivatives. In some examples, the fibrous filler is wood pulp. Without wishing to be bound by theory, it is believed that including fibrous filler in an aerosolisable formulation may increase the tensile strength of the material. This may be particularly advantageous in examples wherein the aerosolisable formulation or aerosol generating material is provided as a sheet, such as when a sheet circumscribes a rod of aerosolisable or aerosol generating material.

[0276] The aerosol-former material may comprise one or more constituents capable of forming an aerosol. In some examples, the aerosol-former material may comprise one or more of glycerol, propylene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol, 1,3-butylene glycol, erythritol, meso-Erythritol, ethyl vanillate, ethyl laurate, a diethyl suberate, triethyl citrate, triacetin, a diacetin mixture, benzyl benzoate, benzyl phenyl acetate, tributyrin, lauryl acetate, lauric acid, myristic acid, and propylene carbonate. In heated products, the aerosol-former material can be present in an amount of greater than 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14% or 15% by weight of the aerosol-generating material.

[0277] The consumable may comprise one or more further constituents. In particular, one or more further constituents may be selected from one or more active agents, and / or one or more functional constituents. In some examples, it may be desirable for the composition to comprise only some of the chemical markers disclosed herein, and this composition combined or used with a known active or flavourant, such as menthol or CBD, in a consumable to create a cigarette-like experience with an added sensation or effect.

[0278] The active agent as used herein may be a physiologically active material, which is a material intended to achieve or enhance a physiological response. The active agent may, for example, be selected from nutraceuticals, nootropics, psychoactives. The active substance may beDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0279] naturally occurring or synthetically obtained. The active agent may comprise for example nicotine, caffeine, taurine, theine, vitamins such as B6 or B12 or C, melatonin, cannabinoids, or constituents, derivatives, or combinations thereof. The active substance may comprise one or more constituents, derivatives or extracts of tobacco, cannabis or another botanical. In some examples, the active substance is a legally permissible recreational drug. In some examples, the active agent comprises nicotine. In some examples, the active agent comprises caffeine, melatonin, or vitamin B12.

[0280] In some examples, the active agent may comprise one or more constituents, derivatives or extracts of cannabis, such as one or more cannabinoids or terpenes. Cannabinoids are a class of natural or synthetic chemical compounds that act on cannabinoid receptors (i.e., CB1 and CB2) in cells that repress neurotransmitter release in the brain. Cannabinoids are cyclic molecules exhibiting particular properties such as the ability to cross the blood-brain barrier with ease. Cannabinoids may be naturally occurring (phytocannabinoids) from plants such as cannabis, (endocannabinoids) from animals, or artificially manufactured (synthetic cannabinoids). Cannabis species express at least 85 different phytocannabinoids, and these may be divided into subclasses, including cannabigerols, cannabichromenes, cannabidiols, tetrahydrocannabinols, cannabinols and cannabinodiols, and other cannabinoids.

[0281] In some examples, the at least one cannabinoid may be selected from cannabigerol (CBG), cannabigerolic acid (CBGA), cannabichromene (CBC), cannabichromenic acid (CBCA), cannabidiol (CBD), cannabidolic acid (CBDA), tetrahydrocannabinol (THC), including its isomers A6a,10a-tetrahydrocannabinol (A6a,10a-THC), A6a(7)-tetrahydrocannabinol (A6a(7)-THC), A8-tetrahydrocannabinol (A8-THC), A9-tetrahydrocannabinol (A9-THC), A10-tetrahydrocannabinol (A10-THC), A9, 11 -tetrahydrocannabinol (A9,11-THC), tetrahydrocannabinolic acid (THCA), cannabinol (CBN), cannabinolic acid (CBNA), and cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM) and combinations thereof. According to one embodiment, the at least one cannabinoid may be selected from cannabigerol (CBG), cannabichromene (CBC), cannabidiol (CBD), tetrahydrocannabinol (THC), cannabinol (CBN) and combinations thereof.

[0282] Naturally derived cannabinoids are generally present in their carboxylated form. In this regard, cannabidiol (CBD) and cannabidolic acid (CBDA) are the respective decarboxylated and carboxylated forms.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0283] The cannabinoid referred to herein may be present in either the carboxylated or decarboxylated form. Exemplary carboxylated cannabinoid in this regard include cannabigerolic acid (CBGA), cannabichromenic acid (CBCA), cannabinolic acid (CBNA), tetrahydrocannabinolic acid (THCA), cannabidolic acid (CBDA) and combinations thereof.

[0284] As noted herein, the active substance may comprise or be derived from one or more botanicals or constituents, derivatives or extracts thereof. As used herein, the term “botanical” includes any material derived from plants including, but not limited to, extracts, leaves, bark, fibres, stems, roots, seeds, flowers, fruits, pollen, husk, shells or the like. Alternatively, the material may comprise an active compound naturally existing in a botanical, obtained synthetically. The material may be in the form of liquid, gas, solid, powder, dust, crushed particles, an extrudate, granules, pellets, shreds, strips, sheets, or the like. Example botanicals are tobacco, eucalyptus, star anise, hemp, cocoa, cannabis, fennel, lemongrass, peppermint, spearmint, rooibos (Aspalathus linearis), chamomile, flax, ginger, ginkgo biloba, hazel, hibiscus, laurel, licorice (liquorice), matcha, mate, orange skin, papaya, rose, sage, tea such as green tea or black tea, thyme, clove, cinnamon, coffee, aniseed (anise), basil, bay leaves, cardamom, coriander, cumin, nutmeg, oregano, paprika, rosemary, saffron, lavender, lemon peel, mint, juniper, elderflower, vanilla, Wintergreen, beefsteak plant, curcuma, turmeric, sandalwood, cilantro, bergamot, orange blossom, myrtle, cassis, valerian, pimento, mace, damien, marjoram, olive, lemon balm, lemon basil, chive, carvi, verbena, tarragon, geranium, mulberry, ginseng, theanine, theacrine, maca, ashwagandha, damiana, guarana, chlorophyll, baobab or any combination thereof. The mint may be chosen from the following mint varieties: Mentha Arventis, Mentha c.v., Mentha niliaca, Mentha piperita, Mentha piperita citrata c.v., Mentha piperita c.v, Mentha spicata crispa, Mentha cardifolia, Memtha longifolia, Mentha suaveolens variegata, Mentha pulegium, Mentha spicata c.v. and Mentha suaveolens.

[0285] In some examples, the active agent comprises or is derived from one or more botanicals or constituents, derivatives or extracts thereof and the botanical is tobacco. In some examples, the active agent comprises or is derived from one or more botanicals or constituents, derivatives or extracts thereof and the botanical is selected from eucalyptus, star anise, cocoa and hemp. In some examples, the active agent comprises or is derived from one or more botanicals or constituents, derivatives or extracts thereof and the botanical is selected from rooibos and fennel. In some examples, the consumable may include a botanical material in addition to any plant material, e.g. tobacco extract, present in the composition. In some examples, this may be advantageous to include other flavourants and / or aroma compounds and / or active agents in the second plant material.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0286] When nicotine is present in the formulation, it may be present in protonated and / or unprotonated form. In some examples, the formulation comprises nicotine in unprotonated form and nicotine in monoprotonated form. It may also be that small amounts of diprotonated nicotine are present. In one aspect the formulation comprises nicotine in unprotonated form, nicotine in monoprotonated form and nicotine in diprotonated form. As will be understood by one skilled in the art, the protonated form of nicotine may be prepared by reacting unprotonated nicotine with an acid. The acid(s) are one or more suitable acids, such as organic acids. In some examples, the acid is a carboxylic acid. The carboxylic acid may be any suitable carboxylic acid. In some examples, the acid is a mono-carboxylic acid. In some examples, the acid is selected from the group consisting of acetic acid, benzoic acid, levulinic acid, lactic acid, formic acid, citric acid, pyruvic acid, succinic acid, tartaric acid, oleic acid, sorbic acid, propionic acid, phenylacetic acid, and mixtures thereof. In some examples, the acid is benzoic acid and / or levulinic acid. In some examples, the acid is benzoic acid. In alternative examples, the aerosolisable formulation may be free of inorganic acids and their corresponding salts. For example, the aerosolisable formulation may be free of phosphoric acids.

[0287] In some examples, the organic acid may be selected from: phenylacetic acid, acetic acid isovaleric acid; valeric acid; lactic acid; 2-methylvaleric acid; isobutyric acid; 2-methyl butyric acid; levulinic acid; and 3-methyl pentanoic acid.

[0288] Where present, the amount of organic acid present may vary. The formulation may comprise from about 0.01% to about 10% by weight of organic acid, present as one or more organic acids, based on the total weight of the formulation. In some examples, the formulation comprises at least about 0.01%, at least about 0.1 %, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or at least about 10% organic acid by weight, based on the total weight of the formulation. In some preferred examples, the formulation comprises from about 0.01 % to about 5% by weight of organic acid. For example, the formulation comprises an organic acid in an amount of from about 0.1% to about 2.5% by weight of the formulation. In the case where a salt of an organic acid is added (e.g., citric acid anhydrate), the percent by weight is calculated based on the weight of the free acid, not including any counter-ion which may be present.

[0289] In some examples, the further constituent comprises a flavour. As used herein, the terms "flavour" and "flavourant" refer to materials which, where local regulations permit, may be used to create a desired taste, aroma, or other somatosensory sensation in a product for adult consumers. They may include naturally occurring flavour materials, botanicals, extracts ofDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0290] botanicals, synthetically obtained materials, or combinations thereof (e.g., tobacco, cannabis, licorice (liquorice), hydrangea, eugenol, Japanese white bark magnolia leaf, chamomile, fenugreek, clove, maple, matcha, menthol, Japanese mint, aniseed (anise), cinnamon, turmeric, Indian spices, Asian spices, herb, Wintergreen, cherry, berry, red berry, cranberry, peach, apple, orange, mango, clementine, lemon, lime, tropical fruit, papaya, rhubarb, grape, durian, dragon fruit, cucumber, blueberry, mulberry, citrus fruits, Drambuie, bourbon, scotch, whiskey, gin, tequila, rum, spearmint, peppermint, lavender, aloe Vera, cardamom, celery, cascarilla, nutmeg, sandalwood, bergamot, geranium, khat, naswar, betel, shisha, pine, honey essence, rose oil, vanilla, lemon oil, orange oil, orange blossom, cherry blossom, cassia, caraway, cognac, jasmine, ylang-ylang, sage, fennel, wasabi, piment, ginger, coriander, coffee, hemp, a mint oil from any species of the genus Mentha, eucalyptus, star anise, cocoa, lemongrass, rooibos (Aspalathus linearis), flax, ginkgo biloba, hazel, hibiscus, laurel, mate, orange skin, rose, tea such as green tea or black tea, thyme, juniper, elderflower, basil, bay leaves, cumin, oregano, paprika, rosemary, saffron, lemon peel, mint, beefsteak plant, curcuma, cilantro, myrtle, cassis, valerian, pimento, mace, damien, marjoram, olive, lemon balm, lemon basil, chive, carvi, verbena, tarragon, limonene, thymol, camphene), flavour enhancers, bitterness receptor site blockers, sensorial receptor site activators or stimulators, sugars and / or sugar substitutes (e.g., sucralose, acesulfame potassium, aspartame, saccharine, cyclamates, lactose, sucrose, glucose, fructose, sorbitol, or mannitol), and other additives such as charcoal, chlorophyll, minerals, botanicals, or breath freshening agents. They may be imitation, synthetic or natural ingredients or blends thereof. They may be in any suitable form, for example, liquid such as an oil, solid such as a powder, or gas.

[0291] The flavour may be added to the consumable as part of a so-called “flavour block”, where one or more flavours are blended together and then added to the substrate material.

[0292] In some examples, the flavour comprises menthol, spearmint and / or peppermint. In some examples, the flavour comprises flavour components of cucumber, blueberry, citrus fruits and / or redberry. In some examples, the flavour comprises eugenol. In some examples, the flavour comprises flavour components extracted from tobacco. In some examples, the flavour comprises flavour components extracted from cannabis.

[0293] In some examples, the flavour may comprise a sensate, which is intended to achieve a somatosensory sensation which are usually chemically induced and perceived by the stimulation of the fifth cranial nerve (trigeminal nerve), in addition to or in place of aroma or taste nerves, and these may include agents providing heating, cooling, tingling, numbing effect. A suitable heat effect agent may be, but is not limited to, vanillyl ethyl ether and aDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0294] suitable cooling agent may be, but not limited to eucalyptol (if not already present in the composition), WS-3.

[0295] Where present, a flavouring agent may be included in the formulation in an amount up to about 10% by weight, such as up to about 5% by weight, such as up to about 1% by weight of the formulation. In some examples, a flavouring agent is present in an amount of from about 0.01% to about 5% by weight, preferably in an amount of from about 0.1% to about 2.5% by weight of the formulation, and more preferably in an amount of from about 0.25% to about 1 % by weight of the formulation.

[0296] The one or more other functional constituents may comprise one or more of colouring agents, pH regulators, preservatives, stabilizers, and / or antioxidants. A colouring agent may be employed in amounts sufficient to provide the desired physical attributes to the product. The colouring agent may, for example, alter the visual appearance of the formulation and further, may colour-match the formulation to other components of the aerosolisable formulation or other components of a consumable comprising the formulation. In some examples, the colouring agent may be included so as to confer the aerosolisable formulation with a brown appearance.

[0297] It is also possible to add further compounds to the extract compositions which may be absent from a tobacco extract, but present in smoke formed by burning the same tobacco used to form the extract. These compounds are discussed further below and termed the ‘smoke markers’. When present, each of the smoke markers may be included in an amount of about 0.1 to about 30 ug / mL, such as from about 0.1 to about 20 ug / mL. This may, in some examples, further improve the cigarette-like experience provided by the extract composition of the present disclosure when used in a substance delivery system.

[0298] Plant Extracts

[0299] In some examples, one or more of the compounds are obtained by extraction from a natural source, e.g. a tobacco material. The present disclosure is not, however, limited to obtaining one or more compounds via an extraction method. The present disclosure includes the formulation of a partially or totally synthetic or artificial composition. In some examples, at least one of the compounds may be a synthetic compound. In this manner, the composition may include one or more compounds which are naturally derived, e.g. from a tobacco source, and one or more compounds which are synthetic (e.g. obtained commercially or otherwise synthesised).DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0300] In some examples, the total number of chemical compounds present in the composition is less than about 800, such as less than about 600, or less than about 500. By total number of chemical compounds is meant the number of different chemical compounds present at a detectable level by e.g. GC-MS.

[0301] In some examples, the total content of any one of the tobacco-specific nitrosamines (TSNAs) in the composition, namely N-nitrosonornicotine (NNN), N’-nitrosoanatabine (NAT), N-nitrosoanabasine (NAB) and nicotine-derived nitrosamine ketone (NNK), is less than about 4 µg / g, or less than about 3 µg / g. This may be an indication that at least one compound is obtained from a tobacco extract.

[0302] In some examples, the composition may include formaldehyde and / or acetaldehyde. This may be an indication that at least one compound is obtained from a tobacco extract. The amount of formaldehyde and / or acetaldehyde is less than about 4 µg / g.

[0303] In some examples, the composition may include at least one plant material, optionally wherein the plant material is a tobacco extract. The tobacco extract may include one or more of the compounds defined above for the composition. The disclosures made herein in relation to the compounds thus apply equally to a tobacco extract comprising one or more of said compounds. In other examples, one or more of said compounds may be added to the tobacco extract to form a composition of the present disclosure. In some examples, the composition is a tobacco extract.

[0304] When present or used to obtain one or more compounds of the composition, any tobacco extract may be used. In some examples, the tobacco extract may be an extract of Virginia tobacco, Burley tobacco, Oriental tobacco, or a combination thereof. In some examples, the tobacco extract comprises an extract of Virginia tobacco. The tobacco may be cured; in some examples, the tobacco is cured. Cured tobacco may be flue-cured, air-cured and / or sun-cured. In some examples, the tobacco extract comprises an extract of flue-cured Virginia tobacco.

[0305] In some examples, the tobacco from which one or more compounds may be extracted (referred to herein as raw tobacco) may include tobacco leaf. In some examples, the tobacco leaf may be defined by its nicotine content. In some examples, the nicotine content of the tobacco leaf may be from about 0.5 to about 8.0 wt%, based on the total weight of the leaf. In some examples, the nicotine content of the tobacco leaf may be from about 0.8 to about 7.5 wt%, based on the total weight of the leaf. In some examples, the nicotine content of the tobacco leaf may be from about 1.5 to about 7.5 wt%, based on the total weight of the leaf.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0306] In some examples, the tobacco leaf may be defined by its sugar content. Exemplary nicotine and sugar contents for flue-cured Virginia tobacco are about 0.9 to about 5.5 wt% nicotine and about 4 to about 25 wt% sugar. Exemplary nicotine and sugar contents for air-cured Burley tobacco are about 1.5 to about 6.5 wt% nicotine and less than about 1 to about 2 wt% sugar. Exemplary nicotine and sugar contents for sun-cured Oriental tobacco are about 0.5 to about 3.0 wt% nicotine and about 8 to about 12 wt% sugar. Exemplary nicotine and sugar contents for fire-cured dark tobacco are about 2.5 to about 6 wt% nicotine and less than about 1 to about 2 wt% sugar.

[0307] In some examples, the tobacco extract is obtained from cured Virginia tobacco, cured Burley tobacco, cured Oriental tobacco, or a combination thereof. In some examples, the tobacco extract is obtained from flue-cured Virginia tobacco, air-cured Burley tobacco, sun-cured oriental tobacco, or a combination thereof.

[0308] The solvent extraction method disclosed herein for forming the composition is not particularly limited. It may be a simultaneous distillation extraction method, a supercritical fluid extraction method or another extraction method known in the art. Other extraction methods are also known including maceration or percolation or hot reflux or Soxhlet extraction, or microwave extraction. The method may also include further steps such as filtration, fractionation, pyrolysis, adsorption, distillation and / or purification. _Extraction methods are provided in WO 2026 / 021165 A1, US 2026 / 0053181 A1, WO 2026 / 026620 A1, WO 2026 / 045589 A1, and WO 2026 / 045587 A1 which are herein incorporated by reference for such methods.

[0309] Hot reflux and microwave extraction are described in WO 2026 / 045589 A1 and WO 2026 / 045587 A1 (Shenzhen Smoore Technology LTD), which are herein incorporated by reference for such methods. For example, a hot reflux extraction method is disclosed using an SF-2L small-scale reflux apparatus. In this method, tobacco leaves are placed in a roundbottom flask which is heated by an electric heating mantle. Evaporated ethanol and water are passed into a condenser and refluxed. The extraction temperature is 95°C and the extraction time is 120 minutes. After extraction, a filtrate is collected and the extract is concentrated using a rotary evaporator. Further examples of hot reflux extraction can be found in WO 2026 / 045587 A1.

[0310] Simultaneous distillation extraction is a technique in which the steps of isolation and extraction of certain compounds from a sample can be achieved simultaneously. In some example, a simultaneous distillation extraction (SDE) process can be used for forming tobacco extracts in which process comprises (i) providing a tobacco material, (ii) subjecting the tobacco material to steam distillation, and (iii) extracting one or more volatile compounds of interest from theDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0311] tobacco material with a solvent, wherein the distillation step (ii) and extraction step (iii) are carried out simultaneously. The method may comprise mixing a quantity of tobacco (e.g. ground tobacco) with water. This solution may have a pH of from about 5 to about 7, such as from about 5.5 to about 6.5. Glass beads may be added to prevent bumping. The solution may then be heated, for example, to a temperature of from about 100°C to about 130°C.

[0312] The distillation step (ii) and extraction step (iii) being carried out simultaneously means that in some examples, the SDE method may be carried out in a single step. In some examples, an additional distillation and / or extraction step is excluded. In some examples, the SDE method is carried out in a single apparatus with no additional processing prior to removal of the extracted product from the apparatus.

[0313] In some examples the solvent used for extraction is a non-polar solvent. In some examples the solvent used for extraction is a polar solvent. As used herein, the term “polar” refers to a solvent having a dielectric constant of greater than or equal to 15. As used herein, the term “non-polar” refers to a solvent having a dielectric constant of less than 15.

[0314] In some examples, the solvent is immiscible with water. In some examples, the solvent comprises an organic solvent. The term “organic” is understood in the art; it is typically considered to be a solvent comprising carbon. In some examples, the solvent is selected from: n-butanol, cyclohexane, dichloromethane, ethyl acetate, heptane, hexane, methyl-t-butyl ether, 2-butanone, pentane, diisopropyl ether, diethyl ether, and mixtures thereof. The use of a mixture of pentane and ether is non-toxic and may be easily replaced by ethanol after extraction of the volatile compounds of interest has been achieved.

[0315] In some examples, further processing of the extracted product may be carried out. The further processing may comprise a purifying step which comprises replacing the solvent used for extraction with another solvent suitable for use in a composition as described herein. In some examples, such a purifying step comprises replacing the solvent used for extraction with ethanol.

[0316] In some examples a supercritical fluid extraction (SFE) process used for forming tobacco extracts is employed. The process may comprise contacting tobacco with an extraction solvent under supercritical conditions. In some examples, the extraction solvent comprises, or is, supercritical carbon dioxide. In some examples, no co-solvent is present.

[0317] In some examples, the SFE process is performed at a pressure of from about 50 to about 500 bar. In some examples, the temperature during extraction may range from about 25°C to about 90°C. In some examples, supercritical extraction is performed using a flow rate of extractionDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0318] solvent of from about 0.5 to about 5 kg / hr. In some examples, the pressure is varied during the SFE process, for example to collect fractions having varying volatility. In such examples, a lower pressure (e.g. about 50 to about 200 bar) may be used for a first period of time, followed by a higher pressure (e.g. from about 200 to about 500 bar) for a second period of time. The first period of time may be from about 0.5 to about 2 hours. The second period of time may be from about 0.5 to about 2 hours. In some examples, the two fractions or extracts are combined. In some examples the two fractions or extracts are collected separately and not combined. In some examples, only the extract from the second extraction is retained and / or used.

[0319] In some examples the supercritical conditions comprise a pressure of from about 50 to about 500 bar, such as from about 100 to about 400 bar or from about 100 to about 300 bar. In some examples, the supercritical conditions comprise an extraction temperature of from about 25°C to about 90°C, such as from about 30°C to about 70°C, or from about 40°C to about 60°C. In some examples, the extraction process may be performed from about 0.5 to about 5 hours, such as from about 1 to about 4 hours, from about 2 to about 3 hours, or about 2.5 hours. In some examples, the supercritical extraction may be performed using a flow rate of extraction solvent (e.g. carbon dioxide) of from about 0.5, 0.8, or 1 kg / hr to about 2, 3 or 5 kg / hr. In some examples, supercritical extraction is performed using a flow rate of extraction solvent (e.g. carbon dioxide) of from about 0.1 to about 5 kg / hr, such as from about 0.8 to about 3 kg / hr, from about 1 to about 3 kg / hr, or about 1 kg / hr. The skilled person will understand that these pressure, temperature, time and flow rate conditions may be combined with one another.

[0320] In some examples, the SFE process involves placing ground tobacco in a container (e.g., 260 g of ground tobacco in a 1 L container) and using supercritical carbon dioxide as an extraction solvent at 1 kg / h and ethanol as a co-solvent (30%). The pressure of the system is set to 250 bar and the temperature maintained at 75 degrees. The extracts are collected for a period of 2 hours.

[0321] Tobacco Particles

[0322] In some examples, the composition may further comprise a plurality of solid tobacco particles. In some examples, the solid tobacco particles remain as distinct entities within the composition, such that the composition can be considered to be in the form of a heterogeneous mixture. For example, the solid tobacco particles may be at least partially suspended in the composition. As used herein, the term “at least partially suspended” means that the solid tobacco particles are distributed within the composition (e.g. a liquid composition), wherein the distribution of said particles within the formulation is notDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0323] necessarily even. For example, the spatial distribution of the particles may be biased towards one portion of the composition. In some examples, the suspension of the particles may be enhanced by agitation, for example shaking or inversion, such as when comprised in an article and / or in a non-combustible aerosol provision system, including in use.

[0324] In some examples the solid tobacco particles are visible, for example to the naked eye. It will be understood that the term “visible” as used herein means that the solid tobacco particles can be seen, e.g. when present in a composition according to the present disclosure, such as by a user. Thus, the presence of the solid tobacco particles in the composition of the present disclosure can be readily apparent to a user (e.g. of a substance provision system), such as by the presence of distinct, visible particles in said composition. By “the naked eye”, the term will be understood to mean that the solid tobacco particles can be seen e.g. by a user without magnification or other visual enhancement. In various examples, the solid tobacco particles are visible under ambient conditions, for example normal temperature (e.g. from about 15 °C to about 25 °C) and pressure (e.g. about 1 atm). In various examples, the tobacco particles may be visible in one or more stages of use but not all. For example, the tobacco particles may be visible in the composition as such. In further examples, the tobacco particles may be visible when the composition is comprised in an article. For example, the article may be partially or completely transparent such that the presence of the tobacco particles in the formulation in the article may be determined by a user by viewing the article. In some examples, the article may comprise at least a transparent portion, wherein the transparent portion may be configured so that the solid tobacco particles are visible to the naked eye, e.g. to a user of the article. In further examples, the tobacco particles may be visible when the composition is comprised in a substance delivery system. For example, the article and substance delivery system may each comprise at least a transparent portion wherein said transparent portions are arranged such that the tobacco particles are visible to the naked eye, e.g. to a user of the substance delivery system.

[0325] The size of the solid tobacco particles is not necessarily limited. In some examples, the solid tobacco particles have a size of at least about 50 pm, at least about 0.1 mm or at least about 0.5 mm. In some examples, the solid tobacco particles have a size of up to about 15 mm, up to about 10 mm or up to about 2 mm. In further examples, the solid tobacco particles have a size of from about 50 pm to about 15 mm, from about 0.1 mm to about 10 mm or from about 0.5 mm to about 2 mm. The particle size may be determined by sieving. For example, a recited lower particle size limit means that the particles will not pass through a sieve with a mesh size of said limit, and an upper particle size limit means that the particles will pass through a sieve with a mesh size of said limit. Thus, a particle size of at least 50 pm means that the particles are retained on a sieve with a 50 pm mesh. In another example, a particleDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0326] size of up to about 15 mm means that the particles are not retained on a sieve (i.e. the particles pass through the sieve) with a 15 mm mesh.

[0327] In some examples, at least about 80%, at least about 90%, at least about 95% or at least about 99% by weight of the solid tobacco particles have a size according to any of the foregoing examples.

[0328] The tobacco material from which the tobacco particles according to the present disclosure are obtained or obtainable from is not necessarily limited. For example, the tobacco material may be as described in any of the examples of tobacco / tobacco material described herein. In some examples, the tobacco material from which the tobacco particles are obtained or obtainable from may include tobacco leaf. In further examples the tobacco leaf may be defined by its nicotine and / or sugar content as described herein.

[0329] In some examples, the tobacco particles are obtained or obtainable by grinding a tobacco material, such as tobacco leaf. The means by which the tobacco material may be ground is not limited and a person of skill in the art of the present disclosure will be able to select suitable apparatus and / or methods for grinding a tobacco material such as tobacco leaf as part of their common general knowledge. In some examples, the tobacco particles are obtained or obtainable by mill grinding a tobacco material. For instance, using a cutting mill, examples of which are commercially available and known to a person of skill in the art. For instance, a FRITSCH PULVERISETTE 19 cutting mill. In some examples, tobacco particles are obtained or obtainable by grinding, such as mill grinding, a tobacco material and sieving the ground tobacco material, e.g. to obtain a particle size such as those disclosed herein. In some examples the sieving may be integrated into the grinding process, e.g. the grinding apparatus such as a cutting mill may comprise a sieve.

[0330] In some examples, the tobacco material from which the tobacco particles are obtained may have been processed. In some examples, the tobacco particles may be obtained or obtainable from a tobacco material that has been extracted with at least one solvent. For example, a waste or by-product of an extraction process such as disclosed in further detail herein. In advantageous examples, the tobacco material may have been ground, e.g. to form solid tobacco particles, prior to the extraction process such that the solid tobacco particles may be used directly after the extraction process in the composition of the present disclosure.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0331] Particle sizes

[0332] The particle size of an aerosol impacts the sensorial experience for a user, particularly altering the taste, mouth feel and lung delivery. An increase in particle size is generally related to higher flavour deposition and impact I irritation. Typically, a particle size > 1um is linked to harshness (higher impact I irritation), but can depend on other variables such as the formulation itself, particularly flavour and protonation, which may negate these effects.

[0333] The present invention will now be described with reference to the following non-limiting examples.

[0334] Examples

[0335] Example 1

[0336] Two tobacco extracts were formed from different blends of flue-cured Virginia, air-cured Burley, sun-cured Oriental, and fire-cured Dark tobacco using a solvent extraction method. Each of these extracts were a composition to provide a tobacco aroma, the composition comprising one or more compounds selected from: C6 to C18 substituted pyrazines, sesquiterpenes or terpene alcohols, C5 to C24 fatty acids, C7 to C18 aromatic alcohols, C3 to C24 aliphatic esters, C8 to C18 aromatic esters, and C4 to C18 lactones. E-liquids were then prepared with 8.5% w / w or 10% w / w of the extract (TLE) in 60 / 40 PG / VG. The formulation details are set out in the table below.

[0337]

[0338] The table below summarises Dv10, Dv50 and Dv90 particle size percentiles of the 3 aerosolised formulations. Each liquid sample was tested 3 times in both:

[0339] • device A) a commercially-available Vuse Pro aerosol generating system; and

[0340] • device B) a modified aerosol generating system, as illustrated in figure 4, having the mesh of figure 2.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0341]

[0342] Figures 5-7 are particle size distribution plots for liquid samples 1-3 respectively. These results show that:

[0343] • all 3 formulations provide suitable particle size distributions in the commercially- available Vuse Pro system (device A); and

[0344] • the system (device B) of figure 4 consistently reduces the Dv90 particle size for all 3 liquid samples, which reduces harshness and so may be more desirable for some users to improve the sensorial experience.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0345] In other words, all 3 samples consistently provide fewer particles exceeding 1.0 um and have a lower Dv90 when used with an aerosol provision system comprising an aerosol generator having the mesh of figure 2.

[0346] Example 2

[0347] Further analysis was carried out to supplement the observations in the previous Examples. Throughout this description, ‘tobacco liquid extract’ may be referred to as ‘TLE’.

[0348] Four sample e-liquids were tested in non-combustible aerosol provision systems according to the present disclosure. The same device was used for all four samples.

[0349] The objective of this Example was to determine whether any differences between the four sample e-liquids could be determined, with a focus on FMC-like taste and overall satisfaction score.

[0350] The methodology of this test was sequential monadic testing (product placement with rotation). In this case, participants (n=355) were provided with the non-combustible aerosol provision systems containing the sample e-liquid and asked to use the products as they would normally as part of their daily routine for 2 days.

[0351] Following placement, participants completed a sensorial evaluation by being asked a series of questions about the samples. The key drivers of an FMC-like taste that were evaluated included the tobacco taste likeability, aroma likeability, authenticity, smoothness of taste, aftertaste and sweetness.

[0352] The key drivers of overall satisfaction that were evaluated include the drivers of the FMC-like taste, and additionally include physiological factors, such as the immediacy and sufficiency of the physiological response to the e-liquid, and sensorial factors, including irritation, chest sensation, smoothness of vapour and mouth drying, each of which contribute to the overall FMC experience and thus contribute to an overall satisfaction.

[0353] Table 1 below details each sample tested.

[0354] Table 1

[0355]

[0356] DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0357]

[0358] Two comparative examples were also provided to participants and evaluated.

[0359] This first comparative example is a commercially available tobacco-flavour e-liquid, which was chosen due to its popularity with smokers in the UK market.

[0360] The second comparative example is a tobacco stick for use in a heated tobacco device, which was chosen due to its similarity with factory made cigarette, such as similarity in FMC-like taste and overall FMC-like experience.

[0361] The results of the comparative analysis are provided in Table 2 below:

[0362] Table 2

[0363]

[0364] Key: “+” indicates improvement versus comparative example

[0365] “ — ” indicates parity versus comparative example

[0366] It can be seen that sample 3 has a superior FMC-like taste compared to comparative example 1 and has an equivalent scoring of the FMC-like taste when compared to comparative example 2, indicating that the presently disclosed extracts advantageously provide an FMC-like experience, such as FMC-like taste, to the consumer.

[0367] The four samples were further tested as indicated above, however participants were divided between a full flavour (FF) solus and none-full flavour (NFF) solus. Full flavour cigarettes typically have a stronger, sometimes described as harsher or more intense, taste, whereas non-full flavour cigarettes are typically described as having a smoother taste

[0368] Results of the comparative analysis are provided below in Table 3.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0369] Table 3

[0370]

[0371] Key: “+” indicates improvement versus comparative example

[0372] “ — ” indicates parity versus comparative example

[0373] It can be seen that samples 2 and 3 achieve an equivalent scoring of FMC-like taste in both the FF and NFF groups when compared to comparative example 2. Furthermore, the overall satisfaction score of samples 1-4 achieves an equivalent scoring to the FF group when compared to comparative example 2.

[0374] Accordingly, it can be seen that a full flavour user has a similar overall satisfaction when using the disclosed samples 1-4 or when using the second comparative example. This advantageously demonstrates that, amongst a population full flavour users, the disclosed blends are able to provide just as effective experience as a commercially available product which more closely resembles an FMC.

[0375] Example 3

[0376] To further supplement the observations in the previous Examples, sample e-liquids were tested in a non-combustible aerosol provision system. The same device was used for all samples.

[0377] The methodology of this test was sequential monadic product placement with block rotation. In this case, participants (n=300) were FMC users who were provided with a non-combustible aerosol provision system containing the sample e-liquid back-to-back and asked to use the products as they would normally as part of their daily routine for 2 days.

[0378] A comparative example was also analysed - comparative example 2, as described above. Following placement, participants completed a sensorial evaluation and participants were scored on; Whether the e-liquid had an FMC-like taste and / or experience comparable with comparative example 2. Participants were asked a series of questions about the sample andDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0379] the samples were assigned a mean score on a 7-point scale. The following drivers of FMC authentic taste were assessed: (1) Tobacco-taste likability; (2) aftertaste likeability; (3) aroma likeability; (4) taste intensity; (5) taste amount; and (6) taste consistency. (1)-(6) are listed in order of their importance for FMC authentic taste, with (1) being the most important and (6) being the least important.

[0380] The samples being assessed are detailed in table 4 below.

[0381] Table 4

[0382] The samples being assessed were:

[0383]

[0384] The results of the sensorial evaluation are provided in table 5 below.

[0385] Table 5

[0386]

[0387] * indicates significant difference at 95% confidence intervall

[0388] As can be seen, the top 5 drivers of FMC-like authenticity in both samples 5 and 6 are not significantly different from comparative example 2, indicating said samples provide an overall FMC-like experience.

[0389] Example 4

[0390] Further analysis was carried out to supplement the observations in the previous Examples. Four sample e-liquids were tested in non-combustible aerosol provision systems according to the present disclosure. The same device was used for all four samples.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0391] The methodology of this test was sequential monadic testing (product placement with rotation). In this case, participants (n=355) were provided with the non-combustible aerosol provision systems containing the sample e-liquid and asked to use the products as they would normally as part of their daily routine for 2 days.

[0392] Following placement, participants completed a sensorial evaluation by being asked a series of questions about the samples. In particular, the sensorial factors evaluated which contribute to the overall FMC experience included irritation, chest sensation, smoothness of vapour and mouth drying. Participants assessed whether the factors were just right (“JR”), too much or enough (e.g. too sweet, not sweet enough or just right).

[0393] Table 6 below details each sample tested.

[0394] Table 6

[0395]

[0396] Two comparative examples were also analysed.

[0397] The first comparative example (“comparative example 1”) is a commercially available tobacco-flavour e-liquid, which was chosen due to its popularity with smokers in the UK market.

[0398] The second comparative example (“comparative example 2”) is a tobacco stick for use in a heated tobacco device, which was chosen due to its similarity with factory made cigarette (FMC), such as similarity in FMC-like taste and overall FMC-like experience.

[0399] The results of the comparative analysis are provided in Tables 7 and 8 below.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0400] Table 7: Sensation analysis vs comparative example 1

[0401]

[0402] Table 8: Sensation analysis vs comparative example 2

[0403]

[0404] Key: “+” indicates improvement versus comparative example (90% Confidence Interval) “ — ” indicates parity versus comparative example (90% Confidence Interval) All samples provide multiple FMC-like sensations, including irritation, smooth vapour and mouth drying that is at least equivalent to the FMC-like sensations provided by comparative example 1.

[0405] Additionally, all samples advantageously provide a level of irritation that is at least equivalent to comparative example 2, thus providing an e-liquid which more closely provides an overall FMC-like experience.

[0406] Example 5

[0407] Four sample e-liquids were tested in a non-combustible aerosol provision system. The same device was used for each sample. The objective of this Example was to determine whether any differences between the four sample e-liquids could be determined, with a focus on irritation and overall FMC experience.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0408] The methodology of this test was sequential monadic testing in which the participants (n=12) evaluated multiple samples one at a time, completing the full sensory attributes for each sample before moving on to the next. A rating was given between 1 and 10, 1 being the lowest and 10 being the highest. The results are shown below; “NSD” means no significant difference versus the benchmark.

[0409] A comparative example was also analysed (“comparative example 1”), which is a commercially available tobacco-flavour e-liquid, which was chosen due to its popularity with smokers in the UK market. In this case, comparative example 1 contained 18.6 mg / ml nicotine.

[0410] Table 9 below details each sample tested.

[0411] Table 9

[0412]

[0413] Sample 1 of Table 9 was set as the benchmark against which irritation was evaluated amongst the samples containing extract 1.

[0414] Sample 4 of Table 9 was set as the benchmark against which irritation was evaluated amongst the samples containing extract 2.

[0415] The results of the comparative analysis are provided below in Tables 10 and 11.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0416] Table 10

[0417]

[0418] Comparative analysis reveals that sample 1 (Extract 1 with 18.6 mg / ml nicotine and 8% TLE inclusion) has a statistically equivalent irritation and FMC experience in comparison to samples 2 and 3. However, comparative example 1 demonstrated decreased irritation and FMC experience versus the benchmark (sample 1). Accordingly, sample 1 delivers an improved FMC-like experience, including in respect of irritation, versus a commercially available tobacco-flavour e-liquid.

[0419] Table 11

[0420]

[0421] Comparative analysis reveals that sample 4 (Extract 2 with 18.6 mg / ml of nicotine and 7% TLE inclusion) has improved irritation in comparison to samples 5 and 6, advantageously demonstrating that increased irritation can be effected by increasing nicotine and / or reducing TLE %.

[0422] Furthermore, comparative example 1 demonstrated decreased irritation versus the benchmark (sample 4) and samples 5 and 6. Accordingly, samples 4-6 deliver an improved FMC-like experience in respect of irritation, versus a commercially available tobacco-flavour e-liquid. Sample 4 was also shown to deliver an overall closer FMC experience versus comparative example 1.

[0423] Participants were further tasked with identifying the location of irritation according to a check-all-that-apply (“CATA”) approach. In particular, participants were asked to indicate whether irritation was detected in the mouth, nose, tongue, chest, throat and / or other for each of samples 1-6 and comparative example 1.

[0424] The results are shown in Figures 8 & 9.

[0425] It was found that for Extract 1, as nicotine level was increased from 14.0 mg / ml to 18.6 mg / ml, directionally more irritation was perceived on the tongue.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0426] It was found that for Extract 2, as nicotine level was increased from 14.0 mg / ml to 18.6 mg / ml, directionally more irritation was perceived on the mouth.

[0427] Example 6

[0428] To further supplement the observations in the previous Examples, sample e-liquids were tested in a non-combustible aerosol provision system as defined herein. The same device was used for all samples.

[0429] The methodology of this test was sequential monadic product placement with block rotation. In this case, participants (n=300) were FMC users who were provided with aerosol provision systems containing the sample e-liquid back-to-back and asked to use the products as they would normally as part of their daily routine for 2 days.

[0430] A comparative example was also analysed - comparative example 2, as described above. Following placement, participants completed a sensorial evaluation and participants were scored on; Whether the e-liquid had an FMC-like taste and / or experience comparable with comparative example 2.

[0431] Participants were asked a series of questions about the sample. The following drivers of FMC authentic sensation were assessed: (1) smooth taste; (2) irritation; (3)mouth drying; (4) sweetness; (5) bitterness; and (6) warmth of vapour. Participants assigned driver (1) was assigned a mean score on a 7-point scale. Participants assessed whether drivers (2)-(6) were just right (“JR”), too much or enough (e.g. too sweet, not sweet enough or just right) and the percentage of each calculated.

[0432] The samples being assessed are detailed in the table below.

[0433] Table 12

[0434] The samples being assessed were:

[0435]

[0436] The results of the sensorial evaluation are provided in the tables below.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0437] Table 13

[0438]

[0439] * indicates significant difference at 95% confidence interval

[0440] As can be seen, each of the drivers of FMC-like sensation authenticity in both samples 5 and 6 are not significantly different from comparative example 2, indicating said samples provide an overall FMC-like experience.

[0441] Example 7

[0442] Overview

[0443] A non-targeted GCMS study was performed to analyse tobacco extracts as disclosed herein to identify the compounds present using chromatogram deconvolution and El library matching. A list of compounds of interest was searched for in the untargeted results and the concentration of said compounds was calculated over three replicates.

[0444] The concentration of compounds of interest were calculated over a period of 12 months, with values generated at T = 0, 1, 3, 6, 9 and / or 12 months.

[0445] Tobacco extract was stored at:

[0446] • 25(±2)°C at 60(±5) % relative humidity (“Ambient” or “AMB”), or

[0447] • 5(±3)°C (“Cold”).

[0448] Materials and Methods

[0449] 300 pL of a tobacco extract sample was weighed into a 50 mL centrifuge tube. 10 mL of ethyl acetate was added to each sample which was then spiked with 100 pL of an internal standard (ISTD) solution. The ISTD was 1,4-dibromobenzene. Samples were shaken at 300 rpm for approximately 2 hours on a platform shaker.

[0450] Aliquots of each sample were transferred into 2 mL GC autosampler vials for analysis. Samples were analyzed via GCMS operating in Scan mode using a Restek Rxi 5ms column (30m x 0.25mm x 0.25pm).DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0451] Agilent Unknowns Analysis software was used to process all samples using chromatogram deconvolution to find compounds whose spectra were then compared against an in house PCDL and NIST 20 for identification.

[0452] Semiquantitative concentration results were obtained from the relative response of identified compounds compared to the ISTD 1-4, dibromobenzene (approximate concentration of 500 ng / mL).

[0453] Results

[0454] Results are provided below in respect of a first and second tobacco extract that were analysed as above.

[0455] Stability of Flavour Compounds

[0456] A number of flavour compounds was determined to be present in the second tobacco extract. These flavour compounds are indicated in the table below, and an exemplary concentration range for each flavour compound is indicated.

[0457] Table 14

[0458]

[0459] DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0460]

[0461] GCMS Scan Flavour Analysis of the second tobacco extract was carried out over a period of 9 months with concentrations of each compound of interest calculated at T = 0, 1, 3, 6, 9 and / or 12 months under ambient or cold conditions.

[0462] A concentration was also calculated after a 1 month accelerated period in which the extract was stored at 40(±2)°C at 75(±5) % relative humidity (“accel”).

[0463] The concentration at T=0 is provided in the Table 15 below, wherein a V” indicates that the concentration remains within the exemplary range provided above.

[0464] Table 15

[0465] 1 2 c y m 2 B

[0466] n 5 t 4 tr 2 M

[0467] k A

[0468] a B

[0469] e B

[0470] a E

[0471] ( y E

[0472] ( L

[0473] d

[0474]

[0475] DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0476]

[0477] As indicated by Tables 14 and 15 above, each of the flavour compounds shown maintain a concentration within the exemplary acceptable range over a period of at least T=3 months (e.g. acetoxyacetate), at least T=6 months (e.g. pentanal) and the majority for a period of T=9 months. Many flavour compounds are stable at T=12 months (e.g. linolenic and palmitic acid).

[0478] A number of flavour compounds was determined to be present in the first tobacco extract.

[0479] These flavour compounds are indicated in the table below, and an exemplary concentration range for each flavour compound is indicated.

[0480] Table 16

[0481]

[0482] DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0483]

[0484] GCMS Scan Flavour Analysis of the first tobacco extract was carried out over a period of 12 months with concentrations of each compound of interest calculated at T = 0, 1, 3, 6, 9 and / or 12 months under ambient or cold conditions.

[0485] A concentration was also calculated after a 1 month accelerated period in which the extract was stored at 40(±2)°C at 75(±5) % relative humidity (“accel”).

[0486] The concentration at T=0 is provided in the Table 17 below, wherein a ” indicates that the concentration remains within the exemplary range provided above.

[0487] Table 17

[0488] LD

[0489] 12

[0490] § I S 2 I c I y m [ 2 I B

[0491] I n § 5 § t § 4 tr

[0492]

[0493] DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0494]

[0495] As indicated by Tables 16 and 17 above, each of the flavour compounds shown maintain a concentration within the exemplary acceptable range over a period of at least T=3 months (e.g. acetoxyacetate), at least T=6 months (e.g. pentanal) and the majority for a period of T=9 months. Many flavour compounds are stable at T=12 months (e.g. linolenic and palmitic acid).

[0496] Example 8

[0497] A difference between e-liquids obtained from tobacco liquid extracts (TLEs) compared to synthetic tobacco is the presence of naturally occurring acids in the tobacco extract. To understand the chemical and sensorial behaviour of such acids and identify alternatives toDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0498] acids presently included in synthetic tobacco e-liquids (lactic acid and benzoic acid), a study was performed to determine the binding affinities of acids found naturally in tobacco to their cognate receptor, TRPV1. The reference compounds used in this study were benzoic acid and lactic acid. These molecules were selected as benchmarks to contextualize and compare the binding affinities obtained for the compounds of interest.

[0499] The test compounds were: phenylacetic acid, heptanoic acid, 3-methylpentanoic acid, 2-methylvaleric acid, levulinic acid, 2-methylbutyric acid, isovaleric acid, valeric acid, isobutyric acid, butyric acid, and acetic acid.

[0500] The affinity values considered throughout the analysis are the binding affinity scores (kcal / mol) obtained from compound-receptor interaction analyses derived from molecular docking simulations. These values represent the predicted strength of interaction between each ligand (test or reference compound) to the simulated molecular receptor.

[0501] It will be appreciated by one skilled in the art that each of the compounds may be capable of binding to suitable receptors to act as the required agonist, antagonist or inhibitor. When a potential modulator interacts with a receptor then the interaction will have a given binding energy. The binding energy may be determined based on the follow equation:

[0502]

[0503] More specifically, the modulator and receptor involves several molecular interactions (e.g., van der Waals, electrostatic, hydrogen bonds, hydrophobic, and others) and physical-chemical complementarity among the receptor and the modulator. The protein structure file (receptor) may be retrieved from the Protein Data Bank and was described using electron microscopy model. The details are as follows: TRPV1: PDB: 7LR0, https: / / www. res b. orq / structu re / 7 LRO, DOI: 10.2210 / pdb7lr0 / pdb. The receptors hydrogen atoms may be added, according to appropriate hybridization geometry, to those atoms based on built-in modules to add partial charges, protonation states followed by bond orders assignment and set up rotatable bonds of the receptors.

[0504] Active site pockets of a protein molecule are the sites where the potential modulators bind to a protein. To perform these experiments, one may use one simulation box that determinates the searching area for the modulators. This theoretical procedure may be performed using the TRPV1 grid-box size with dimensions of x=20 A, y= 20 A, z=20 A and a center coordinates of X=106.82 A, Y= 82.40 A, Z = 90.48 A.

[0505] Gibbs free energy of binding (FEB in Kcal / mol) for complexes structures of a receptor -modulator may be calculated using a scoring function which approximates the chemicalDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0506] potentials (ΔGbind). The docking free energy of binding (FEBd0Ck) is defined by AGbindvalues for all docked poses of the formed complexes (protein- modulators) and include the internal steric energy of a given protein and modulators which can be expressed as the sum of individual molecular mechanics terms of standard-chemical potentials.

[0507]

[0508] A more negative value of FEB (kcal / mol) implies a higher affinity between the receptor and the different types of modulator substrates. The docking simulation results may be categorized as energetically unfavorable when the Gibbs free energy of the formed complexes is Gbind> 0 kcal / mol, pointing either to extremely low or complete absence of binding affinity, otherwise they are categorized having medium to high docking affinity.

[0509] The docking simulation results may be categorized as energetically unfavorable when the Gibbs free energy of the formed complexes is ΔGbind≥ 0 kcal / mol, pointing either to extremely low or complete absence of binding affinity.

[0510] In summary, the FEB threshold is 0 kcal / mol. FEB values higher than 0 means an absence of affinity for the receptor. If FEB is lower than 0 kcal / mol, there was affinity for receptors. Lowest FEB values means a better affinity for receptor.

[0511] The Δ affinity represents the difference in binding affinity between a test compound and a reference compound. This value is calculated relative to each reference compound (benzoic acid and lactic acid). For each receptor, the Δ affinity is computed as the absolute value of the difference between the docking affinity of a target compound and the docking affinity of the reference compound, according to the following expression:

[0512]

[0513] By way of example:

[0514] • Butyric acid (test compound): affinity = -4.477 kcal / mol

[0515] • Benzoic acid (reference): affinity = -6.169 kcal / mol

[0516] Δaffinity =| -6.169 - (-4.477) |= 1.692 kcal / mol

[0517] This A affinity calculation was performed for both reference compounds, across all test compounds. The results of the affinity analysis are provided in Table 18 below.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0518] In Table 18, the affinity value of each acid for its receptor (kcal / mol) is described by whether it was more negative (i.e., a higher affinity) or less negative (i.e., a lower affinity) than the affinity value calculated for benzoic acid as a reference.

[0519] In Table 18, the compounds have been ranked in order of their Δ affinity, wherein 1 represents the smallest A affinity and 12 represents the largest A affinity, versus benzoic acid as a reference.

[0520] Table 18

[0521]

[0522] It can be seen how all acids tested were comparable in terms of A affinity to either benzoic acid or lactic acid.

[0523] Example 9

[0524] Following the results of the binding affinity study, the test acid compounds were analysed for their transfer efficiency from e-liquid to aerosol.

[0525] Acids were measured in e-liquid and aerosol sample types using Gas Chromatography coupled with Mass Spectrometry (GC-MS) and were compared based on how much was proportionally detected in terms of w / w (mass balance). E-liquid measurements were a direct calculation. For aerosol measurements, using a smoking machine, the amount of e-liquid vaped was determined based on the mass of the remaining e-liquid. Accordingly, the acidsDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0526] were measured in the residual e-liquid, initial e-liquid and in the emission captured in a filter pad used in a smoking machine.

[0527] To measure the acids in the e-liquid, 10 mg of e-liquid was weighed into a vial- and 990 µL of isopropanol added. 10 pL of Naphthalene_d8 at 10000 ppm was then added and the solution vortexed for 15 seconds, checking for complete homogenisation. The solution was then injected into the GC-MS.

[0528] To measure the acids in an aerosol sample, the e-liquid was vaped using a smoking machine (LM4) aligned with the angle to 15° and connect to an e-liquid device set to the holder, which contains a filter pad (e.g. a Cambridge filter (ml)). The smoking machine was programmed with the following specifications: 70 puffs, 3 seconds puff duration, 55 mL puff volume, 30 sec puff interval.

[0529] The analyzed extract is generated from the smoking of 70 puffs and 15°. The smoking analysis is carried out in a linear smoking machine with one impinger containing 10 mL of extractive solution and 45 mm filter pad. Each sample was analyzed in at least 3 replicates. The filter pads used in the smoking process were conditioned for 48 hours at 25°C and a maximum relative humidity of 60%.

[0530] After smoking using the smoking machine, the filter pad was transferred to a 125 mL Erlenmeyer flask and 10 mL of extractive solution added. The samples were shaken in an orbital shaker at 250rpm for 30 minutes. The samples were filtered with an aliquot of each sample into a 2mL vial, which was then injected into the GC-MS.

[0531] The concentration of each acid in the aerosol can thus be calculated as follows:

[0532] Concentration (mg / mL)=((Aa / Ai-l)x C) / D

[0533] Aa = analyte area;

[0534] Ai = Internal standard area;

[0535] I = Standard curve intercept;

[0536] C = Internal Standard concentration

[0537] D = Slope

[0538] Accordingly, the transfer efficiency can be calculated based on how much was proportionally detected in terms of w / w in the e-liquid versus the aerosol.

[0539] The results of this study are set out in Table 19 below.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0540] Table 19

[0541]

[0542] It can be seen how the transfer efficiency of each of the acids is close to 100%. Hence, a further study was performed to determine and compare the sensorial contributions of the acids in the FMC-like space.

[0543] Sensory attribute models are obtained from data collected through structured sensory evaluations, in which a trained panel quantifies the intensity of specific attributes (such as mouthful of smoke, impact, irritation, mouth drying, mouth coating, taste intensity, tobacco aroma, brightness, darkness and draw resistance) using standardized scales.

[0544] The trained panel refers to a sensory panel composed of assessors who are specifically selected and trained to evaluate products in a structured and consistent way. They are familiar with a defined sensory vocabulary and with assessing the intensity of specific attributes (such as aroma, taste, mouthfeel and related sensations) using standardized scales and reference standards.

[0545] In parallel, while the sample is being assessed by the panel, it is also analyzed through a High-Throughput Screening (HTS) platform (or GC-MS Gas Chromatography-Mass Spectrometry), enabling the acquisition of its chemical fingerprint in an objective andDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0546] reproducible manner. The chemical fingerprint is analyzed through machine learning models that can predict sensory aspects of FMC based on chemistry (as described in Soares et al.

[0547] 2020. Journal of Chemometrics).

[0548] The integration of these sensory and chemical datasets allows the development of statistical or multivariate models that link perceptual attributes to specific chemical profiles.

[0549] The correlation coefficient is a statistical metric that quantifies both the strength and the direction of the relationship between two variables, typically ranging from -1 to +1: positive values indicate that an increase in a given variable is associated with an increase in the sensory attribute (increase), whereas negative values indicate that an increase in the variable is associated with a decrease in the sensory attribute (decrease), enabling an objective interpretation of how chemical composition influences sensory perception.

[0550] Table 20 provides the direction for each tested compound in each attribute.

[0551] Table 20

[0552]

[0553] As can be seen from the above data, whilst all acids had a comparable binding affinity and close to 100% transfer efficiency from the e-liquid to the aerosol, only isovaleric acid, 3-DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0554] methylpentanoic acid, phenylacetic acid, valeric acid, levulinic acid, 2-methylbutyric acid, isobutyric acid and acetic acid were identified as markers of FMC-like sensorial attributes. Specifically, each of these acids were found to contribute to drivers of FMC-like sensation. For example, each acid demonstrates an increase in respect of irritation, indicating that the presence of each acid promotes irritation. Additional benefits of these acids are outlined below. Isovaleric acid, 3-methylpentanoic acid, phenylacetic acid, 2-methyl butyric acid, isobutyric acid and acetic acid each are capable of darkening the flavour profile. Valeric acid and levulinic acid each are capable of brightening the flavour profile.

[0555] As noted hereinabove, it may be desirable to ‘shift’ the profile of an aroma from a noncombustible substance delivery system to replicate and / or emphasise characteristics to mimic those of specific FMC products. For instance, as exhibited by certain tobacco varieties or blends thereof, such as Virginia, Burley, Oriental and the like. For example, Virginia may in some examples be characterised as brighter than other tobacco varieties, which may be associated with characteristics such as hay-like notes, lightness / mildness of flavour and or strength, and / or smoothness. Other varieties such as Oriental may be considered to have more complexity, depth and / or aromaticity. In some examples of FMC products, lighter and darker tobaccos may be combined in varying proportions to combine the foregoing characteristics to reflect consumer preference.

[0556] By the terms “bright” and “dark”, is therefore meant modifying the aroma to “brighten” or “darken” towards that of a ‘bright’ tobacco and / or a ‘dark’ tobacco.

[0557] The various examples described herein are presented only to assist in understanding and teaching the claimed features. These examples are provided as a representative sample of examples only, and are not exhaustive and / or exclusive. It is to be understood that advantages, examples, functions, features, structures, and / or other aspects described herein are not to be considered limitations on the scope of the invention as defined by the claims or limitations on equivalents to the claims, and that other examples may be utilised and modifications may be made without departing from the scope of the claimed invention. Various examples of the invention may suitably comprise, consist of, or consist essentially of, appropriate combinations of the disclosed elements, components, features, parts, steps, means, etc., other than those specifically described herein. In addition, this disclosure may include other inventions not presently claimed, but which may be claimed in future.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0558] Terminology

[0559] Delivery System

[0560] As used herein, the term “delivery system” is intended to encompass systems that deliver at least one substance to a user in use, and includes:

[0561] combustible aerosol provision systems, such as cigarettes, cigarillos, cigars, and tobacco for pipes or for roll-your-own or for make-your-own cigarettes (whether based on tobacco, tobacco derivatives, expanded tobacco, reconstituted tobacco, tobacco substitutes or other smokable material);

[0562] non-combustible aerosol provision systems that release compounds from an aerosolgenerating material without combusting the aerosol-generating material, such as electronic cigarettes, tobacco heating products, and hybrid systems to generate aerosol using a combination of aerosol-generating materials; and

[0563] aerosol-free delivery systems that deliver the at least one substance to a user orally, nasally, transdermally or in another way without forming an aerosol, including but not limited to, lozenges, gums, patches, articles comprising inhalable powders, and oral products such as oral tobacco which includes snus or moist snuff, wherein the at least one substance may or may not comprise nicotine.

[0564] Combustible Aerosol Provision System

[0565] According to the present disclosure, a “combustible” aerosol provision system is one where a constituent aerosol-generating material of the aerosol provision system (or component thereof) is combusted or burned during use in order to facilitate delivery of at least one substance to a user.

[0566] In some embodiments, the delivery system is a combustible aerosol provision system, such as a system selected from the group consisting of a cigarette, a cigarillo and a cigar. In some embodiments, the disclosure relates to a component for use in a combustible aerosol provision system, such as a filter, a filter rod, a filter segment, a tobacco rod, a spill, an aerosol-modifying agent release component such as a capsule, a thread, or a bead, or a paper such as a plug wrap, a tipping paper or a cigarette paper.

[0567] Non-Combustible Aerosol Provision System

[0568] According to the present disclosure, a “non-combustible” aerosol provision system is one where a constituent aerosol-generating material of the aerosol provision system (or component thereof) is not combusted or burned in order to facilitate delivery of at least one substance to a user.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0569] In some embodiments, the delivery system is a non-combustible aerosol provision system, such as a powered non-combustible aerosol provision system. In some embodiments, the non-combustible aerosol provision system is an electronic cigarette, also known as a vaping device or electronic nicotine delivery system (END), although it is noted that the presence of nicotine in the aerosol-generating material is not a requirement. In some embodiments, the non-combustible aerosol provision system is an aerosol-generating material heating system, also known as a heat-not-burn system. An example of such a system is a tobacco heating system.

[0570] In some embodiments, the non-combustible aerosol provision system is a hybrid system to generate aerosol using a combination of aerosol-generating materials, one or a plurality of which may be heated. Each of the aerosol-generating materials may be, for example, in the form of a solid, liquid or gel and may or may not contain nicotine. In some embodiments, the hybrid system comprises a liquid or gel aerosol-generating material and a solid aerosolgenerating material. The solid aerosol-generating material may comprise, for example, tobacco or a non-tobacco product.

[0571] Typically, the non-combustible aerosol provision system may comprise a non-combustible aerosol provision device and a consumable for use with the non-combustible aerosol provision device. In some embodiments, the disclosure relates to consumables comprising aerosol-generating material and configured to be used with non-combustible aerosol provision devices. These consumables are sometimes referred to as articles throughout the disclosure.

[0572] In some embodiments, the non-combustible aerosol provision system, such as a non-combustible aerosol provision device thereof, may comprise a power source and a controller. The power source may, for example, be an electric power source or an exothermic power source. In some embodiments, the exothermic power source comprises a carbon substrate which may be energised so as to distribute power in the form of heat to an aerosol-generating material or to a heat transfer material in proximity to the exothermic power source.

[0573] In some embodiments, the non-combustible aerosol provision system may comprise an area for receiving the consumable, an aerosol generator, an aerosol generation area, a housing, a mouthpiece, a filter and / or an aerosol-modifying agent. In some embodiments, the consumable for use with the non-combustible aerosol provision device may comprise aerosol-generating material, an aerosol-generating material storage area, an aerosol-DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0574] generating material transfer component, an aerosol generator, an aerosol generation area, a housing, a wrapper, a filter, a mouthpiece, and / or an aerosol-modifying agent.

[0575] Aerosol-Free Delivery System

[0576] In some embodiments, the delivery system is an aerosol-free delivery system that delivers at least one substance to a user orally, nasally, transdermally or in another way without forming an aerosol, including but not limited to, lozenges, gums, patches, articles comprising inhalable powders, and oral products such as oral tobacco which includes snus or moist snuff, wherein the at least one substance may or may not comprise nicotine.

[0577] In some embodiments, the substance to be delivered may be an aerosol-generating material or a material that is not intended to be aerosolised. As appropriate, either material may comprise one or more active constituents, one or more flavours, one or more aerosol-former materials, and / or one or more other functional materials.

[0578] Active Substance

[0579] In some embodiments, the substance to be delivered comprises an active substance. The active substance as used herein may be a physiologically active material, which is a material intended to achieve or enhance a physiological response. The active substance may for example be selected from nutraceuticals, nootropics, psychoactives. The active substance may be naturally occurring or synthetically obtained. The active substance may comprise for example nicotine, caffeine, taurine, theine, vitamins such as B6 or B12 or C, melatonin, cannabinoids, or constituents, derivatives, or combinations thereof. The active substance may comprise one or more constituents, derivatives or extracts of tobacco, cannabis or another botanical. In one embodiment the active substance is a legally permissible recreational drug. In some embodiments, the active substance comprises nicotine. In some embodiments, the active substance comprises caffeine, melatonin or vitamin B12.

[0580] As noted herein, the active substance may comprise one or more constituents, derivatives or extracts of cannabis, such as one or more cannabinoids or terpenes. The active substance may be CBD or a derivative thereof. As noted herein, the active substance may comprise or be derived from one or more botanicals or constituents, derivatives or extracts thereof. As used herein, the term "botanical" includes any material derived from plants including, but not limited to, extracts, leaves, bark, fibres, stems, roots, seeds, flowers, fruits, pollen, husk, shells or the like. Alternatively, the material may comprise an active compound naturally existing in a botanical, obtained synthetically. The material may be in the form of liquid, gas, solid, powder, dust, crushed particles, granules, pellets, shreds, strips, sheets, or the like.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0581] Example botanicals are tobacco, eucalyptus, star anise, hemp, cocoa, cannabis, fennel, lemongrass, peppermint, spearmint, rooibos, chamomile, flax, ginger, ginkgo biloba, hazel, hibiscus, laurel, licorice (liquorice), matcha, mate, orange skin, papaya, rose, sage, tea such as green tea or black tea, thyme, clove, cinnamon, coffee, aniseed (anise), basil, bay leaves, cardamom, coriander, cumin, nutmeg, oregano, paprika, rosemary, saffron, lavender, lemon peel, mint, juniper, elderflower, vanilla, Wintergreen, beefsteak plant, curcuma, turmeric, sandalwood, cilantro, bergamot, orange blossom, myrtle, cassis, valerian, pimento, mace, damien, marjoram, olive, lemon balm, lemon basil, chive, carvi, verbena, tarragon, geranium, mulberry, ginseng, theanine, theacrine, maca, ashwagandha, damiana, guarana, chlorophyll, baobab or any combination thereof. The mint may be chosen from the following mint varieties: Mentha Arventis, Mentha c.v., Mentha niliaca, Mentha piperita, Mentha piperita citrata c.v., Mentha piperita c.v, Mentha spicata crispa, Mentha cardifolia, Memtha longifolia, Mentha suaveolens variegata, Mentha pulegium, Mentha spicata c.v. and Mentha suaveolens.

[0582] In some embodiments, the active substance comprises or is derived from one or more botanicals or constituents, derivatives or extracts thereof and the botanical is tobacco. In some embodiments, the active substance comprises or derived from one or more botanicals or constituents, derivatives or extracts thereof and the botanical is selected from eucalyptus, star anise, cocoa and hemp. In some embodiments, the active substance comprises or derived from one or more botanicals or constituents, derivatives or extracts thereof and the botanical is selected from rooibos and fennel.

[0583] Flavours

[0584] In some embodiments, the substance to be delivered comprises a flavour. As used herein, the terms "flavour" and "flavourant" refer to materials which, where local regulations permit, may be used to create a desired taste, aroma or other somatosensorial sensation in a product for adult consumers. They may include naturally occurring flavour materials, botanicals, extracts of botanicals, synthetically obtained materials, or combinations thereof (e.g., tobacco, cannabis, licorice (liquorice), hydrangea, eugenol, Japanese white bark magnolia leaf, chamomile, fenugreek, clove, maple, matcha, menthol, Japanese mint, aniseed (anise), cinnamon, turmeric, Indian spices, Asian spices, herb, Wintergreen, cherry, berry, red berry, cranberry, peach, apple, orange, mango, clementine, lemon, lime, tropical fruit, papaya, rhubarb, grape, durian, dragon fruit, cucumber, blueberry, mulberry, citrus fruits, Drambuie, bourbon, scotch, whiskey, gin, tequila, rum, spearmint, peppermint, lavender, aloe vera, cardamom, celery, cascarilla, nutmeg, sandalwood, bergamot,DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0585] geranium, khat, naswar, betel, shisha, pine, honey essence, rose oil, vanilla, lemon oil, orange oil, orange blossom, cherry blossom, cassia, caraway, cognac, jasmine, ylang-ylang, sage, fennel, wasabi, piment, ginger, coriander, coffee, hemp, a mint oil from any species of the genus Mentha, eucalyptus, star anise, cocoa, lemongrass, rooibos, flax, ginkgo biloba, hazel, hibiscus, laurel, mate, orange skin, rose, tea such as green tea or black tea, thyme, juniper, elderflower, basil, bay leaves, cumin, oregano, paprika, rosemary, saffron, lemon peel, mint, beefsteak plant, curcuma, cilantro, myrtle, cassis, valerian, pimento, mace, damien, marjoram, olive, lemon balm, lemon basil, chive, carvi, verbena, tarragon, limonene, thymol, camphene), flavour enhancers, bitterness receptor site blockers, sensorial receptor site activators or stimulators, sugars and / or sugar substitutes (e.g., sucralose, acesulfame potassium, aspartame, saccharine, cyclamates, lactose, sucrose, glucose, fructose, sorbitol, or mannitol), and other additives such as charcoal, chlorophyll, minerals, botanicals, or breath freshening agents. They may be imitation, synthetic or natural ingredients or blends thereof. They may be in any suitable form, for example, liquid such as an oil, solid such as a powder, or gas.

[0586] In some embodiments, the flavour comprises menthol, spearmint and / or peppermint. In some embodiments, the flavour comprises flavour components of cucumber, blueberry, citrus fruits and / or redberry. In some embodiments, the flavour comprises eugenol. In some embodiments, the flavour comprises flavour components extracted from tobacco. In some embodiments, the flavour comprises flavour components extracted from cannabis.

[0587] In some embodiments, the flavour may comprise a sensate, which is intended to achieve a somatosensorial sensation which are usually chemically induced and perceived by the stimulation of the fifth cranial nerve (trigeminal nerve), in addition to or in place of aroma or taste nerves, and these may include agents providing heating, cooling, tingling, numbing effect. A suitable heat effect agent may be, but is not limited to, vanillyl ethyl ether and a suitable cooling agent may be, but not limited to eucolyptol, WS-3.

[0588] Aerosol-generating material

[0589] Aerosol-generating material is a material that is capable of generating aerosol, for example when heated, irradiated or energized in any other way. Aerosol-generating material may, for example, be in the form of a solid, liquid or semi-solid (such as a gel) which may or may not contain an active substance and / or flavourants. The aerosol-generating material may comprise one or more active substances and / or flavours, one or more aerosol-former materials, and optionally one or more other functional material.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0590] The aerosol-generating material may comprise a binder, such as a gelling agent, and an aerosol former. Optionally, a substance to be delivered and / or filler may also be present. Optionally, a solvent, such as water, is also present and one or more other components of the aerosol-generating material may or may not be soluble in the solvent. In some embodiments, the aerosol-generating material is substantially free from botanical material. In particular, in some embodiments, the aerosol-generating material is substantially tobacco free.

[0591] The aerosol-generating material may comprise or be in the form of an aerosol-generating film. The aerosol-generating film may comprise a binder, such as a gelling agent, and an aerosol former. Optionally, a substance to be delivered and / or filler may also be present. The aerosol-generating film may be substantially free from botanical material. In particular, in some embodiments, the aerosol-generating material is substantially tobacco free. The aerosol-generating film may have a thickness of about 0.015 mm to about 1 mm. For example, the thickness may be in the range of about 0.05 mm, 0.1 mm or 0.15 mm to about 0.5 mm or 0.3 mm. The aerosol-generating material may comprise more than one film, and the thickness described herein may refer to the aggregate thickness of those films.

[0592] The aerosol-generating film may be continuous. For example, the film may comprise or be a continuous sheet of material. The sheet may be in the form of a wrapper, it may be gathered to form a gathered sheet or it may be shredded to form a shredded sheet. The shredded sheet may comprise one or more strands or strips of aerosol-generating material. The aerosol-generating film may be discontinuous. For example, the aerosol-generating film may comprise one or more discrete portions or regions of aerosol-generating material, such as dots, stripes or lines, which may be supported on a support. In such embodiments, the support may be planar or non-planar.

[0593] The aerosol-generating film may be formed by combining a binder, such as a gelling agent, with a solvent, such as water, an aerosol-former and one or more other components, such as one or more substances to be delivered, to form a slurry and then heating the slurry to volatilise at least some of the solvent to form the aerosol-generating film. The slurry may be heated to remove at least about 60 wt%, 70 wt%, 80 wt%, 85 wt% or 90 wt% of the solvent.

[0594] The aerosol-generating material may comprise or be an “amorphous solid”. In some embodiments, the aerosol-generating material comprises an aerosol-generating film that is an amorphous solid. The amorphous solid may be a “monolithic solid”. The amorphous solid may be substantially non-fibrous. In some embodiments, the amorphous solid may beDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0595] a dried gel. The amorphous solid is a solid material that may retain some fluid, such as liquid, within it. In some embodiments, the amorphous solid may, for example, comprise from about 50wt%, 60wt% or 70wt% of amorphous solid, to about 90wt%, 95wt% or 100wt% of amorphous solid.

[0596] The amorphous solid may be substantially free from botanical material. The amorphous solid may be substantially tobacco free.

[0597] Aerosol-former material

[0598] The aerosol-former material may comprise one or more constituents capable of forming an aerosol. In some embodiments, the aerosol-former material may comprise one or more of glycerol, propylene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol, 1,3-butylene glycol, erythritol, meso-Erythritol, ethyl vanillate, ethyl laurate, a diethyl suberate, triethyl citrate, triacetin, a diacetin mixture, benzyl benzoate, benzyl phenyl acetate, tributyrin, lauryl acetate, lauric acid, myristic acid, and propylene carbonate.

[0599] Functional material

[0600] The one or more other functional materials may comprise one or more of pH regulators, colouring agents, preservatives, binders, fillers, stabilizers, and / or antioxidants.

[0601] Substrate

[0602] The material may be present on or in a support, to form a substrate. The support may, for example, be or comprise paper, card, paperboard, cardboard, reconstituted material, a plastics material, a ceramic material, a composite material, glass, a metal, or a metal alloy. In some embodiments, the support comprises a susceptor. In some embodiments, the susceptor is embedded within the material. In some alternative embodiments, the susceptor is on one or either side of the material.

[0603] Consumable

[0604] A consumable is an article comprising or consisting of aerosol-generating material, part or all of which is intended to be consumed during use by a user. A consumable may comprise one or more other components, such as an aerosol-generating material storage area, an aerosol-generating material transfer component, an aerosol generation area, a housing, a wrapper, a mouthpiece, a filter and / or an aerosol-modifying agent. A consumable may also comprise an aerosol generator, such as a heater, that emits heat to cause the aerosolgenerating material to generate aerosol in use. The heater may, for example, comprise combustible material, a material heatable by electrical conduction, or a susceptor.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0605] Susceptor

[0606] A susceptor is a material that is heatable by penetration with a varying magnetic field, such as an alternating magnetic field. The susceptor may be an electrically-conductive material, so that penetration thereof with a varying magnetic field causes induction heating of the heating material. The heating material may be magnetic material, so that penetration thereof with a varying magnetic field causes magnetic hysteresis heating of the heating material. The susceptor may be both electrically-conductive and magnetic, so that the susceptor is heatable by both heating mechanisms. The device that is configured to generate the varying magnetic field is referred to as a magnetic field generator, herein.

[0607] Aerosol-modifying agent

[0608] An aerosol-modifying agent is a substance, typically located downstream of the aerosol generation area, that is configured to modify the aerosol generated, for example by changing the taste, flavour, acidity or another characteristic of the aerosol. The aerosol-modifying agent may be provided in an aerosol-modifying agent release component, that is operable to selectively release the aerosol-modifying agent. The aerosol-modifying agent may, for example, be an additive or a sorbent. The aerosol-modifying agent may, for example, comprise one or more of a flavourant, a colourant, water, and a carbon adsorbent. The aerosol-modifying agent may, for example, be a solid, a liquid, or a gel. The aerosolmodifying agent may be in powder, thread or granule form. The aerosol-modifying agent may be free from filtration material.

[0609] Aerosol generator

[0610] An aerosol generator is an apparatus configured to cause aerosol to be generated from the aerosol-generating material. In some embodiments, the aerosol generator is a heater configured to subject the aerosol-generating material to heat energy, so as to release one or more volatiles from the aerosol-generating material to form an aerosol. In some embodiments, the aerosol generator is configured to cause an aerosol to be generated from the aerosol-generating material without heating. For example, the aerosol generator may be configured to subject the aerosol-generating material to one or more of vibration, increased pressure, or electrostatic energy.

[0611] The present disclosure relates to aerosol delivery systems (which may also be referred to as vapour delivery systems) such as nebulisers or e-cigarettes. Throughout the following description the term “e-cigarette” or “electronic cigarette” may sometimes be used, but it will be appreciated this term may be used interchangeably with aerosol delivery system / deviceDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643

[0612] and electronic aerosol delivery system / device. Furthermore, and as is common in the technical field, the terms "aerosol" and "vapour", and related terms such as "vaporise", "volatilise" and "aerosolise", may generally be used interchangeably.

[0613] Aerosol delivery systems (e-cigarettes) often, though not always, comprise a modular assembly comprising a reusable device part and a replaceable (disposable / consumable) cartridge part. Often, the replaceable cartridge part will comprise the aerosol generating material and the vaporiser (which may collectively be called a ‘cartomizer’) and the reusable device part will comprise the power supply (e.g. rechargeable power source) and control circuitry. It will be appreciated these different parts may comprise further elements depending on functionality. For example, the reusable device part will often comprise a user interface for receiving user input and displaying operating status characteristics, and the replaceable cartridge device part in some cases comprises a temperature sensor for helping to control temperature. Cartridges are electrically and mechanically coupled to the control unit for use, for example using a screw thread, bayonet, or magnetic coupling with appropriately arranged electrical contacts. When the aerosol generating material in a cartridge is exhausted, or the user wishes to switch to a different cartridge having a different aerosol generating material, the cartridge may be removed from the reusable part and a replacement cartridge attached in its place. Systems and devices conforming to this type of two-part modular configuration may generally be referred to as two-part systems / devices.

[0614] It is common for electronic cigarettes to have a generally elongate shape. For the sake of providing a concrete example, certain embodiments of the disclosure will be taken to comprise this kind of generally elongate two-part system employing disposable cartridges. However, it will be appreciated that the underlying principles described herein may equally be adopted for different configurations, for example single-part systems or modular systems comprising more than two parts, refillable devices and single-use disposables, as well as other overall shapes, for example based on so-called box-mod high performance devices that typically have a boxier shape. More generally, it will be appreciated certain embodiments of the disclosure are based on aerosol delivery systems which are operationally configured to provide functionality in accordance with the principles described herein and the constructional aspects of systems configured to provide the functionality in accordance with certain embodiments of the disclosure is not of primary significance.

[0615] Throughout the disclosure, the terms ‘substantially’, ‘approximately’ and ‘about’ should be considered to mean within + / - 10% unless indicated otherwise.

Claims

DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643Claims1. A mesh for an aerosol generator in an aerosol provision system, the mesh comprising first and second filaments forming interstices, wherein:a. the first and second filaments have different current densities; and b. one or more of the interstices of the mesh are bounded by both the first and the second filaments.

2. A mesh for an aerosol generator in an aerosol provision system, the mesh comprising first and second filaments forming interstices, wherein:a. the first and second filaments have different current densities;b. one or more of the interstices of the mesh are bounded by both the first and the second filaments; andc. the first and second filaments are configured to be respectively heated by a power source to a first temperature T 1 and a second temperature T2, wherein the ratio of T1 to T2 is in the range of 1:1.25 to 1:2.5.

3. A mesh for an aerosol generator in an aerosol provision system, the mesh comprising first and second filaments forming interstices, wherein:a. the first and second filaments have different current densities;b. one or more of the interstices of the mesh are bounded by both the first and the second filaments; andc. the first and second filaments are arranged in the mesh to form:i. two or more low current density zones and at least one high current density zone; ord. two or more high current density zones and at least one low current density zone.

4. The mesh of any preceding claim, wherein the mesh comprises multiple first filaments having a first current density and multiple second filaments having a second current density.

5. The mesh of any preceding claim, wherein the mesh comprises multiple parallel first filaments and multiple parallel second filaments, wherein the first and second filaments are perpendicular.

6. The mesh of any preceding claim, wherein at least two opposing sides of one or more interstices are bounded by filaments having a higher current density than filaments bounding other sides of the one or more interstices.

7. The mesh of any preceding claim, wherein all interstices in the mesh are bounded by both the first and second filaments having different current densities.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 831506438. The mesh of any preceding claim, wherein the second filament(s) have a second current density substantially a factor of 2x to 15x higher than the first current density of the first filament(s).

9. The mesh of any preceding claim, wherein the second filament(s) have a second current density substantially a factor of 3x to 7x, 4x to 6x or 5x higher than the first current density of the first filament(s).

10. The mesh of any preceding claim, wherein the mesh comprises different temperature zones having operating temperatures between 50 and 250°C.

11. The mesh of any preceding claim, wherein the first and second filaments are configured to be respectively heated by a power source to a first temperature T 1 and a second temperature T2, wherein the ratio of T1 to T2 is in the range of 1: 1.25 to 1:2.5.

12. The mesh of any preceding claim, wherein the first and second filaments are arranged in the mesh to form:a. two or more low current density zones and at least one high current density zone; orb. two or more high current density zones and at least one low current density zone.

13. The mesh of any preceding claim, wherein:a. 30-40% of an aerosol generation surface area is configured to operate at 100> T>50; and / orb. 15-25% of an aerosol generation surface area is configured to operate at 150> T>100; and / orc. 10-20% of an aerosol generation surface area is configured to operate at 200> T>150; and / ord. 20-35% of an aerosol generation surface area is configured to operate at 250> T>200, where T is temperature in °C.

14. The mesh of any preceding claim, wherein:a. first filament(s) and / or the second filaments comprise a ferritic iron-chromium- aluminium alloy (FeCrAI alloy); and / orb. the first current density of the first filament(s) is within the range of 0.1 -1.0 x108A / M2; and / orc. the second current density of the second filament(s) is within the range of 2.0- 3.0 x108A / M2.

15. The mesh of any preceding claim, wherein:a. the first filament(s) have a diameter or cross-sectional dimension of substantially 0.12-0.18 mm; and / orDYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 83150643b. the second filament(s) have a diameter or cross-sectional dimension of substantially 0.05-0.09 mm.

16. The mesh of any preceding claim, wherein:a. the first filament(s) have a diameter or cross-sectional dimension of substantially 0.15 mm; and / orb. the second filament(s) have a diameter or cross-sectional dimension of substantially 0.07 mm.

17. An aerosol generator in an aerosol provision system, the aerosol generator comprising a heater for heating a liquid to generate an aerosol and an air path for delivering the aerosol to a user, the heater comprising first and second zones, wherein:a. the first and second zones have different current densities or temperatures;andb. the heater is arranged parallel to the flow of air in the air path.

18. An aerosol generator for an aerosol provision system, the aerosol generator configured to generate aerosol from an aerosolisable formation by resistive heating, the aerosol generator having a mesh comprising filaments forming interstices, wherein:a. 30-40% of the aerosol generation surface area is configured to operate at 100> T>50;b. 15-25% of the aerosol generation surface area is configured to operate at 150> T>100;c. 10-20% of the aerosol generation surface area is configured to operate at 200> T>150; andd. 20-35% of the aerosol generation surface area is configured to operate at 250> T>200, where T is temperature in °C.

19. The aerosol generator of claim 16, wherein the mesh comprises a connecting portion for connecting the filaments to a power supply.

20. The mesh of claims 13-16 or the aerosol generator of any of claims 17-19, wherein the aerosol generation surface area comprises the area of the aerosol generation surface configured to operate between 50 and 250°C in use.

21. The mesh of claims 13-16 or the aerosol generator of any of claims 17-20, wherein the aerosol generation surface area comprises the planar, rectangular area surrounding the mesh.

22. The mesh or aerosol generator of any preceding claim, wherein one or more interstices in the mesh are substantially hexagonal.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 8315064323. The mesh or aerosol generator of any preceding claim, wherein all interstices in the mesh are substantially hexagonal.

24. The mesh or aerosol generator of any preceding claim, wherein the mesh comprises a column or row of substantially hexagonal interstices along a centreline of the mesh.

25. The mesh or aerosol generator of any preceding claim, wherein the filaments provide a lower current density region along a centreline of the mesh, bounded by a higher current density region either side of the centreline.

26. The mesh or aerosol generator of any of claims 22-25, wherein the substantially hexagonal interstices have:a. a major width (lwi) of substantially 1.8-2.2 mm or substantially 2.0 mm; and / or b. a minor width (lW2) of substantially 0.6-1.0 mm or substantially 0.8 mm; and / or c. a length (II) of substantially 0.45-0.50 mm or substantially 0.47 mm; and / or d. an angle 0 between second filaments of substantially 20-40°, 25-35° or substantially 30°; and / ore. an angle 0 between filaments extending from the major width (lwi) to the minor width (lW2) of substantially 20-40°, 25-35° or substantially 30°.

27. The mesh or aerosol generator of any of claims 1 to 21, wherein the interstices are substantially rectangular, having:a. a width (lw) of substantially 1.2-1.6 mm or substantially 1.4 mm; and / or b. a length (II) of substantially 0.45-0.50 mm or substantially 0.47 mm.

28. The mesh or aerosol generator of any of claims 1 to 21, wherein the interstices are square, having substantially equal length and width dimensions of substantially 0.70- 0.90 mm or substantially 0.75-0.85 mm.

29. An aerosol provision system comprising:a. an aerosol generator having the mesh of any preceding mesh claim; or b. the aerosol generator of any preceding aerosol generator claim.

30. The aerosol provision system of claim 29, further comprising a wicking material in contact with the mesh, for supplying aerosolisable material to the mesh, for aerosolisation.

31. The aerosol provision system of claim 29 or 30, further comprising an air flow path extending parallel to a length or width of the mesh.

32. The aerosol provision system of any of claims 29-31, further comprising an aerosolisable formation, the formulation comprising a composition to provide a tobacco aroma, the composition comprising one or more compounds selected from: C6 to C18 substituted pyrazines, sesquiterpenes or terpene alcohols, C5 to C24 fatty acids, C7 to C18 aromatic alcohols, C3 to C24 aliphatic esters, C8 to C18 aromatic esters, and C4 to C18 lactones.DYC ref: P132061PCT1; BAT ref: P20026515W002; AID: 8315064333. A cartridge comprising an aerosolisable formation, the formulation comprising a composition to provide a tobacco aroma, the composition comprising one or more compounds selected from: C6 to C18 substituted pyrazines, sesquiterpenes or terpene alcohols, C5 to C24 fatty acids, C7 to C18 aromatic alcohols, C3 to C24 aliphatic esters, C8 to C18 aromatic esters, and C4 to C18 lactones.

34. The cartridge of claim 33, comprising an aerosol generator and an air flow path extending parallel to a length or width of the aerosolisation surface of the aerosol generator.

35. An aerosolised formulation obtainable by aerosolising a formulation comprising a composition to provide a tobacco aroma, the composition comprising one or more compounds selected from: C6 to C18 substituted pyrazines, sesquiterpenes or terpene alcohols, C5 to C24 fatty acids, C7 to C18 aromatic alcohols, C3 to C24 aliphatic esters, C8 to C18 aromatic esters, and C4 to C18 lactones, wherein the aerosolised formulation has:i. a Dv50 particle size of 0.40 – 0.50 µm; and / orii. a Dv90 particle size of 0.70 – 1.00 µm.

36. The aerosolised formulation of claim 35, having:i. a Dv50 particle size of 0.42 – 0.47 µm; and / orii. a Dv90 particle size of 0.74 – 0.94 µm.

37. The aerosolised formulation of claim 35, having:i. a Dv50 particle size of 0.40 – 0.44 µm; and / orii. a Dv90 particle size of 0.70 – 0.82 µm.

38. The aerosolised formulation of claim 35, having:i. a Dv50 particle size of 0.42 – 0.44 µm; and / orii. a Dv90 particle size of 0.74 – 0.79 µm.

39. The aerosolised formulation of any of claims 35-38, having a Dv10 particle size of 0.20-0.30 µm or 0.24-0.26 µm.

40. A method of generating an aerosol, the method comprising aerosolising an aerosolisable formulation comprising a composition to provide a tobacco aroma, the composition comprising one or more compounds selected from: C6 to C18 substituted pyrazines, sesquiterpenes or terpene alcohols, C5 to C24 fatty acids, C7 to C18 aromatic alcohols, C3 to C24 aliphatic esters, C8 to C18 aromatic esters, and C4 to C18 lactones, to provide an aerosol having:i. a Dv50 particle size of 0.40 – 0.50 µm; and / orii. a Dv90 particle size of 0.70 – 1.00 µm.

41. The method of claim 40, comprising aerosolising the formulation using the mesh, the aerosol generator, the aerosol provision system or the cartridge of any of claims 1-34.